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Abstract 
 
Klebsiella pneumoniae is a Gram-negative rod in the Enterobacteriaceae family, known to cause both 
community- and hospital-acquired infections, especially in immunocompromised patients. In the 
hospital setting, K. pneumoniae strains resistant to antibiotics are increasingly reported to cause 
infections and outbreaks. K. pneumoniae is commonly found to produce extended-spectrum β-
lactamases (ESBLs), which inactivate the most important antibiotics: penicillins, third generation 
cephalosporins and monobactams. The most widespread ESBL enzyme among Enterobacteriaceae 
today is CTX-M-15, which is encoded and spread between strains by plasmids.  
In this project, all (n = 49) ESBLA- producing K. pneumoniae isolates isolated from clinical samples at 
Stavanger University Hospital between 2003 and 2012 were characterized at a molecular level. 
Species identification and antibiotic resistance profile was confirmed by mass spectrometry and the 
Vitek 2 system, respectively. ESBLA-encoding genes were identified by PCR and gene sequencing, 
and clonal relatedness was investigated by pulsed field gel electrophoresis (PFGE) and multilocus 
sequence typing (MLST). Plasmids were identified and characterized by S1-PFGE, PCR-based 
replicon typing and Southern blot hybridization with blaCTX-M, blaSHV and IncFIIK probes.  
All isolates were confirmed ESBLA - producing K. pneumoniae. Identified ESBLA encoding genes 
were typed as blaCTX-M-15 (n = 20), blaCTX-M-3 (n = 1), blaSHV-2 (n = 1), blaSHV-2A (n = 3), blaSHV-5 (n = 
13), and blaSHV-12 (n = 5). The blaCTX-M-15 positive isolates were mainly clonally unrelated, and a 
common plasmid encoding blaCTX-M-15 could not be identified among these isolates. Two blaCTX-M-15 
positive isolates were found to be clonally related to a strain which caused a neonatal intensive care 
unit outbreak at Stavanger University Hospital in 2008 – 2009. Twelve blaSHV-5 positive isolates were 
found to be closely related by PFGE and were typed as sequence type (ST) 29 by MLST. A ~230 kbp 
plasmid was found to bear blaSHV-5 in all blaSHV-5 positive ST29 isolates. 
The most prevalent ESBLA-encoding genes among clinical K. pneumoniae isolates from the Stavanger 
region were blaCTX-M-15 and blaSHV-5. blaSHV-5 positive ST29 isolates have caused sporadic infections 
between 2003 and 2012, and may represent an endemic clone in the Stavanger region and  hospital 
setting. In contrast, the blaCTX-M positive isolates were associated with diverse clones and plasmids.  
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Abbreviations 
 
  
AST Antimicrobial susceptibility testing 
CTX-M Cefotaximase Munich 
ddNTP Dideoxy nucleotide triphosphate 
DIG Digoxigenin 
DNA Deoxyribonucleic acid 
dUTP Deoxyuracil triphosphate 
ECDC European Centre for Disease Prevention and Control 
ESBL Extended-spectrum β-lactamase 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
Inc-type Incompatibility type 
Kbp Kilobase pairs 
Kp Klebsiella pneumoniae 
MALDI-TOF Matrix-assisted laser desorption ionization - time of flight 
MDR Multidrug resistant 
MIC Minimum inhibitory concentration 
MLST Multilocus sequence typing 
PBP Penicillin binding proteins 
PBRT PCR-based replicon typing 
PCR Polymerase chain reaction 
PFGE Pulsed-field gel electrophoresis 
SHV Sulfhydryl variable 
ST Sequence type 
TEM Temoneira 
UPGMA Unweighted pair group method with arithmetic mean 
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1. Introduction 
1.1 Klebsiella pneumoniae 
 
Klebsiella pneumoniae is a Gram-negative rod in the Enterobacteriaceae family. The bacterium is 
found indigenously in soil and waters, but also on mucosal surfaces in mammals, including humans 
[69]. K. pneumoniae is part of the gut microbiota in humans, and is usually not causing disease. 
However, it can cause a variety of infections in immunocompromised patients. It can also cause 
infections when present elsewhere in the body, causing urinary tract infection, respiratory tract 
infection, and bloodstream infection [37]. K. pneumoniae is often associated with nosocomial 
infections, which are infections acquired during hospitalization [80]. K. pneumoniae is often found to 
be resistant to many commonly used antibiotics, making infections caused by this bacterium difficult 
to treat. 
Different taxonomic systems are used to classify the genus Klebsiella. In this thesis, the Ørskov 
classification is used, which divides the species K. pneumoniae into three subspecies; pneumoniae, 
ozaenae and rhinoscleromatis, due to the disease they were found to cause [60]. K. pneumoniae subsp. 
pneumoniae is the subspecies of interest in this study, and is referred to when K. pneumoniae is 
written.  
A bacterias ability to cause disease is known as pathogenicity, while virulence refers to the severity of 
the disease [85], although these terms are used interchangeably. Virulence in K. pneumoniae is based 
on many factors, but the capsule is regarded as the most important [13]. The capsule impairs 
phagocytosis, which increases bacterial survivability. K. pneumoniae is known to have 78 capsule (K) 
types, of which K1, K2, K4 and K5 are considered the most virulent. Many virulence genes have been 
identified, some of which are associated with capsule polysaccharide production and a mucoid 
phenotype, such as rmpA and rmpA2 [25, 63] . Klebsiella species harbouring the rmpA gene have 
been linked to pyogenic liver abscesses [89]. Hypervirulent and hypermucoviscous Klebsiella has 
emerged in the last few years. Hypermucoviscosity is a phenotype characterized by highly viscous and 
sticky colonies, and the term is often used in conjunction with hypervirulence [77]. Hypervirulent K. 
pneumoniae are not, or have not yet, been associated with antibiotic resistance [10]. 
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1.2 β-lactam antibiotics 
 
Antibiotics are antimicrobial compounds that either kill or inhibit bacterial growth. These compounds 
have different targets in the bacterial cell, depending on their mode of action. One of the most 
commonly used types of antibiotics is the β-lactams. The β-lactam antibiotics have the β-lactam ring 
in common, while side chains are variable. There are four groups of β-lactam antibiotics: penicillins, 
monobactams, cephalosporins and carbapenems (figure 1.1) [59]. Examples include ampicillin, 
aztreonam, cefotaxime, and meropenem, respectively. 
Mainly, β-lactams inhibit cell wall synthesis by binding to penicillin binding proteins (PBPs), which 
are crucial enzymes in the cross-linking of peptidoglycan. Peptidoglycan is part of the cell wall of 
prokaryotes, and inhibition of peptidoglycan cross-linking will, as the cell grows, weaken cell integrity 
and eventually lyse the cell. Some β-lactam antibiotics have other modes of action in addition to the 
one described above. For example, cephalosporins might trigger autolytic enzymes in the cell 
envelope, causing cell lysis [59]. Additionally, β-lactams have a different spectrum of activity, as 
some are broad-spectrum antibiotics with activity against both Gram-positive and –negative bacteria, 
while others have a narrow spectrum of activity, like the monobactams (which only affects aerobic 
Gram-negatives) [59]. Third and later generation cephalosporins have an extended spectrum, which 
means they have an even broader range of activity. 
Testing for susceptibility to antibiotics is called antimicrobial susceptibility testing (AST). An isolate 
that has low susceptibility to an antibiotic is said to be resistant. There is a variety of AST procedures 
available today. Commonly used automated AST-systems, such as Vitek 2, measure the minimum 
inhibitory concentration (MIC), which is the lowest concentration (mg/L) of an antibacterial that is 
needed to inhibit bacterial growth [51]. MIC values are set for each drug-bug combination by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST), and are used as a standard 
in most European countries [46]. The gold standard for determining MIC values is the broth culture 
method, where a bacterium is suspended in broth with increasing concentration of an antimicrobial 
agent. No visible growth in a tube means that the concentration of the antimicrobial agent in that tube 
is the minimum inhibitory concentration. AST can also be determined manually by the disk-diffusion 
method, where agar plates and tablets with antimicrobial agents are used. Susceptibility is determined 
by the zone inhibition around each tablet [51]. 
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Figure 1.1: General structures of the four groups of β-lactam antibiotics. A: penicillins, B: monobactams, C: cephalosporins, 
and D: carbapenems. The main structure, the β-lactam ring (marked in teal), is central in each molecule. Variable areas are 
marked with R. 
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1.3 β-lactamases: definition and classification 
 
The β-lactamases are a class of enzymes that hydrolyse the β-lactam ring of penicillins, cephalosporins, 
and other β-lactam antibiotics [58]. This inactivates the drug, giving it a slightly different structure 
(figure 1.2). This structure difference makes it unable to bind to the PBP active site. β-lactamases are 
classified into narrow-spectrum (penicillinases), broad-spectrum (ampicillinases), extended-spectrum 
β-lactamases (ESBLs), and carbapenemases [50], based on range of activity. 
The classical definition of ESBLs is a β-lactamase with hydrolytic activity against penicillins, 
extended-spectrum cephalosporins and monobactams, and is inhibited by clavulanic acid [39]. 
Different classification schemes are available for β-lactamase classification. The most commonly used 
are the Bush-Jacoby-Medeiros [17] and the Ambler [4] schemes, which classify β-lactamases by their 
functional characteristics and primary structure, respectively. Based on these classification systems, an 
enzyme is classified as an ESBL if it is a molecular class A, and a functional class 2be enzyme. 
However, these classification schemes are not convenient for the apparent complexity and quantity of 
enzymes which have been discovered during recent years. In light of this, a new classification scheme 
was suggested by Giske et al. [39]. Briefly, ESBLs are categorized into three classes, ESBLA, ESBLM 
and ESBLCARBA. The ESBLA class contains the former “classical” ESBLs, the CTX-M, TEM, and 
SHV enzymes, along with the less prevalent VEB and PER variants. The ESBLM class is divided into 
ESBLM-C (plasmid-mediated AmpC) and ESBLM-D (OXA-ESBL). The ESBLCARBA class include 
enzymes with the broadest spectrum that confer resistance to extended-spectrum cephalosporins and at 
least one carbapenem. This class is further divided into three subclasses; ESBLCARBA-A, ESBLCARBA-B 
and ESBLCARBA-D. The ESBLA enzymes CTX-M, TEM and SHV are of interest in this study.  
 
 
Figure 1.2: Hydrolysis of the β-lactam ring by action of a β-lactamase. 
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1.4  The ESBLA enzymes 
 
During the last decades, hundreds of new ESBLA enzymes have been identified. The Lahey database 
(www.lahey.org/Studies) contains hundreds of ESBLA protein sequences of most known CTX-M, 
TEM and SHV types. The SHV and TEM enzymes differ from one another only by a few amino acid 
substitutions, while the CTX-M family is widely different [45]. 
The TEM variant was one of the first ESBLs to be detected. First found in 1965, the TEM type β-
lactamase was named after the E. coli infected patient, Temoneira, in Athens, Greece [31]. To date, 
over 220 variants of the TEM enzyme has been identified [18], and the blaTEM gene (encoding the 
enzyme) is usually found on plasmids [67]. TEM-1 has almost no hydrolytic activity against extended-
spectrum cephalosporins, and is therefore not an ESBL enzyme. However, TEM-1 confers resistance 
towards ampicillin and other penicillins. A single amino acid substitution led to the formation of 
TEM-3, which was also capable of hydrolysing cefotaxime (a third generation cephalosporin), and is 
therefore per definition an ESBL [79]. 
The SHV – enzymes were thought to be substrate variable, and were therefore given its name, which 
is short for sulfhydryl variable [67]. There are approximately 193 SHV variants identified to date [18]. 
The non-ESBL enzymes SHV-1 and SHV-11 are chromosomally encoded by most K. pneumoniae 
strains, but can also be plasmid mediated [6, 41]. One amino acid substitution in the SHV-1 sequence 
was discovered in 1983. The new enzyme could effectively hydrolyse third generation cephalosporins, 
such as ceftazidime, and was designated SHV-2 [67]. 
In 1990, Bauernfeind et al. detected an E. coli strain from a German patient, producing a new ESBL 
enzyme. The new enzyme had higher substrate affinity for cefotaxime compared to the SHV-enzymes, 
and was designated CTX-M-1 (Cefotaximase-Munich) [8]. Roughly 160 variants of CTX-M enzymes 
are described to date [18], and the blaCTX-M gene is usually found on plasmids. Whereas the SHV and 
TEM enzymes are related, it seems that the CTX-M enzymes have a different origin. The CTX-M 
variant has a high sequence homology to a chromosomal β-lactamase found in Kluyvera spp. The 
CTX-M enzymes are categorized into five groups, CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and 
CTX-M-25 (figure 1.3), based on sequence homology [12].  
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Figure 1.3: A dendrogram representing groups of the CTX-M family. Branch length is corresponding to amino acid changes. 
Source: Bonnet R., 2004 [12]. 
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1.5  Spread of antibiotic resistant K. pneumoniae 
 
Antimicrobial resistance is emerging worldwide, also in Europe – and in Norway. Antimicrobial 
resistance, especially the emergence of ESBL-producing Gram-negative bacteria such as K. 
pneumoniae, is of great concern due to their limited treatment options. The European Centre for 
Disease Prevention and Control (ECDC) reports a very high amount of K. pneumoniae resistant to 
third generation cephalosporins in southern and eastern Europe in 2013 (figure 1.4). The prevalence of 
ESBL – producing K. pneumoniae varies geographically in Europe. However, even if a low 
prevalence is reported in the Scandinavian countries, NORM (Usage of Antimicrobial Agents and 
Occurrence of Antimicrobial Resistance in Norway) reports an increasing amount of resistant K. 
pneumoniae from 2003 – 2013 (figure 1.5). 
 
Figure 1.4: Proportion of 3rd. generation cephalosporin resistant K. pneumoniae isolates in participating countries in 2013. 
Source: ECDC/EARS-Net (www.ecdc.europa.eu). 
Low prevalence does not mean that outbreaks do not occur. A clonal outbreak occurred at Stavanger 
University Hospital in 2008 – 2009, where an ESBL-producing K. pneumoniae spread in a neonatal 
intensive care unit, infecting a total of 58 infants [73]. Contaminated breast milk was found to be the 
main source of the CTX-M-15 producing K. pneumoniae, and the outbreak ended after screening 
procedures and isolation of the affected patients. 
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Figure 1.5: Prevalence of ESBL-production among E. coli and Klebsiella spp. isolates from blood and urine 2003 – 2013. 
Source: NORM/NORM-VET 2013 (www.vetinst.no). 
1.6 Dissemination of ESBL 
 
1.6.1  Clonal dissemination 
Some bacteria may be more successful than others, depending on many different factors, including 
pathogenicity, virulence, and antibiotic resistance. These are called successful clones, and may be 
present in the environment for a very long time [50]. They spread through normal cell division 
(vertically) and may cause infections or even outbreaks. On a global scale, the E. coli sequence type 
(ST) 131 is spreading clonally, and is mainly associated with CTX-M-15 [65]. Also, the K. 
pneumoniae multiresistant ST11 clone is regarded as internationally prevalent [88]. Specific clones are 
sometimes associated with specific diseases. For example, K. pneumoniae ST23 is known to cause 
pyogenic liver abscesses [40]. 
A bacterial clone is endemic if it persists in a specific geographical area, and is more frequently 
detected in that area compared to other areas [1]. 
1.6.2  Plasmid mediated dissemination 
Plasmids are small, independent genetic elements (figure 1.6) which may be transferred horizontally 
between bacteria by conjugation [52]. Some plasmids have their own origin of replication, which 
make them able to replicate independently from the chromosome, although they do rely on enzymes 
from the host cell to replicate. Usually, plasmids harbour accessory genes (encoding virulence or 
antibiotic resistance traits) which may result in increased bacterial survival in a given environment.  
Some plasmids are present in high numbers in the host cell, i.e. high copy number plasmids, while 
others may have only a few copies present, i.e. low copy number plasmids [52].  
There are many ways to group plasmids. One method is to type the plasmid replicon (origin of 
replication, figure 1.6) using PCR, determining the incompatibility type (Inc-type), or replicon type, of 
the plasmid. One bacterial host cell may contain several different plasmids. However, if two 
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genetically similar plasmids are present in the same cell, only one of them can be maintained. This is 
because the plasmids will compete for the same replication machinery already present in the host cell 
[28]. Genetically similar plasmids are therefore incompatible, and only one of them will be maintained 
after cell division. Two plasmids can only be maintained by one cell if they are of different replicon 
types. One plasmid may also have multiple replicon types. To date, there are 27 known replicon types 
[20]. The ESBL-enzyme CTX-M-15 is frequently associated with low copy-number plasmids of the 
IncF replicon types (e.g. FIIK, FIB, and FII) [21]. Earlier studies have linked CTX-M-15 to plasmids 
of 90 and 180 kilobase pairs (kbp) [49, 90]. 
 
 
Figure 1.6: A schematic diagram of a typical antibiotic resistance plasmid. ESBL-encoding genes and genes conferring 
resistance to other antibiotics are usually found in the variable regions. Source: Brolund, A. 2014 [15].  
Plasmids may harbour ESBL-encoding genes. Along with these, the plasmids may also carry genes 
that confer resistance to other antibiotics, making treatment options even narrower. This is called co-
resistance, and these genes are often carried in conjunction with the ESBL-gene. Bacteria that harbour 
genes that confer resistance to three or more different types of antibiotics are called multidrug resistant 
(MDR) [53]. 
ESBL-encoding genes have been linked to other mobile genetic elements, such as transposons and 
insertion sequences [70]. The genetic environment of various blaCTX-M genes have previously been 
mapped [34], and ISEcp-1-like insertion sequences, along with tnpA-1 to 3 transposons have been 
associated with the mobilization of the blaCTX-M genes [19]. 
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2. Aims of the study 
 
The main aim of the study was to characterize all clinical ESBLA-producing K. pneumoniae isolates 
isolated from clinical samples at Stavanger University Hospital between 2003 and 2012 at a molecular 
level. 
Specific aims: 
1. Determine the types of ESBLA – encoding genes present in clinical K. pneumoniae isolates in 
the Stavanger region 
2. Identify K. pneumoniae clones associated with clinical infection, that may have contributed to 
the spread of ESBLA –encoding genes in the Stavanger region 
3. Identify ESBLA-encoding plasmids that may have contributed to the spread of ESBLA –
encoding genes among K. pneumoniae in the Stavanger region 
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3. Materials and methods 
 
3.1 Bacterial isolate collection 
 
At the Department of Medical Microbiology, Stavanger University Hospital, all Enterobacteriaceae 
isolates from clinical samples have been screened for ESBLA-production since 2003. ESBL-producing 
isolates were stored on freezing-beads at -70 °C. In this study, all clinical ESBLA-producing K. 
pneumoniae isolates identified between 2003 and 2012 were included (n = 55). In addition, three 
isolates associated with an outbreak at the neonatal intensive care unit in 2008 – 2009 were included. 
These isolates were recovered from faecal- and breast milk screening samples. Nine clinical isolates 
were excluded, as they were found to be either non-ESBL producers (n = 2), falsely identified as K. 
pneumoniae (n = 1), not viable after storage (n = 1), or not available (n = 5). 
Of the remaining 49 isolates, 30 were isolated from hospitalized patients (including the three screening 
samples), and 19 from out – patients. The clinical isolates were isolated from urine- (n = 25), 
respiratory- (n = 12), wound- (n = 7), central venous catheter- (n = 1), and blood- (n = 1) samples. The 
screening samples were from faeces (n = 2) and breast milk (n = 1).  
For clarification, all blaCTX-M-15 positive isolates are henceforth called “CTX-M-15 group” isolates and 
the clonally related blaSHV-5 positive isolates are called “SHV-5 group” isolates. Isolate IDs marked 
with “a” and “b” originated from the same patient, but were isolated separately due to phenotypical 
differences. Figure 3.1 illustrates which methods were performed on which isolates. 
 
Figure 3.1: An overview of methods used in this study on which isolates. Isolates are marked in grey, and methods are 
marked in blue. AST = antimicrobial susceptibility testing, MS = mass spectrometry, PFGE = pulsed field gel electrophoresis, 
PBRT = PCR-based replicon typing, MLST = multilocus sequence typing. 
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3.2 ESBLA – screening 
 
All isolates (n = 49) were confirmed to be ESBLA – producing K. pneumoniae by growth on selective 
ESBL – agar and subsequent species identification. 
All isolates were inoculated on two agar plates. Plate one, a selective chromogenic ESBL agar 
(bioMérieux, Marcy l’Étoile, France), was used to confirm ESBLA-production. Plate two was a 
modified MacConkey agar (see appendix A for recipe) with one 30 µg cefotaxime tablet (Rosco 
Diagnostics AS, Taastrup, Denmark). The agar plates were incubated at 35 °C overnight. On plate one, 
growth of blue-green colonies suggested ESBL-producing K. pneumoniae, while brown colonies 
suggested ESBL-producing E. coli (according to the manufacturer). On plate two, cefotaxime 
susceptibility was evaluated by roughly measuring the zone around the cefotaxime disk. 
3.3 Species identification 
 
All isolates were previously identified to the species level. In this study, these results were confirmed 
by mass spectrometry. 
Matrix assisted laser desorption/ionization – time of flight (MALDI-TOF) mass spectrometry is a 
quick and reliable method for bacterial species identification and is presently used in many 
laboratories around the world. Identification of bacterial species by mass spectrometry is based on the 
molecular fingerprint (mass spectrum) of the bacterium. Each fingerprint is highly distinctive, and by 
comparing the fingerprint of the bacterium in question with reference spectra from different species of 
bacteria, the computer can identify the isolate based on similarities between these spectra. The 
spectrum is based on the glycoproteins, lipoproteins and other membrane-bound molecules, which the 
high-energy UV laser irradiates [72]. When these molecules are ionized by the laser, they travel 
through the TOF (time of flight) separator, which separates them by charge and mass. Finally, they 
reach a detector which will send the signal to the computer. The Microflex MALDI-TOF (Bruker 
Daltonik, Bremen, Germany) is presently used for bacterial identification at Stavanger University 
Hospital. The MALDI biotyper CA software is used to analyse MALDI-TOF data. Each isolate is 
given a score based on the similarity between the reference and sample spectrum. The score value is 
from 0 to 3, where 2.3 – 3 is regarded as highly probable species identification [29]. Protocol used is 
presented in box 1. 
 
Box 1: MALDI-TOF analysis protocol, as given by the manufacturer (Bruker Daltonik). 
  
 
MALDI-TOF analysis 
1. Inoculate isolates on blood agar (see recipe in appendix) and incubate overnight at 35 °C.  
2. Pick a single colony with a toothpick, and smear onto the target plate. 
3. Add matrix (1.0 µl) to each sample on the plate. 
4. Let plate dry before MALDI-TOF analysis. 
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3.4 Antimicrobial susceptibility testing 
 
Antimicrobial susceptibility testing (AST) was automatically performed on all isolates by the Vitek 2 
system (bioMérieux, Marcy l’Étoile, France) to determine the antimicrobial susceptibility pattern. 
Vitek 2 utilizes cards that determine the antimicrobial susceptibility pattern of a bacterial isolate. The 
card “AST-N209” was used in this study as it is specifically made for resistance determination for 
Gram-negative rods. The card test susceptibility to the following antibiotics: ampicillin, trimethoprim, 
nitrofurantoin, trimethoprim/sulfamethoxazole, ciprofloxacin, cefuroxime, cefotaxime, ceftriaxone, 
ceftazidime, gentamicin, meropenem, piperacillin/tazobactam, cefoxitin, amoxicillin/clavulanic acid, 
cefuroxime axetil, aztreonam, nalidixic acid, and tobramycin. The samples are drawn into the cards by 
vacuum, and the tube on the card is hermetically sealed. The card contains dehydrated antibiotics, and 
colorimetry is used to detect susceptibility. Colour changes are registered by the computer every 15 
minutes, under a controlled environment [68]. MIC values are calculated and interpreted as R 
(resistant), I (intermediate), or S (sensitive) depending on the MIC value. The classification of MIC 
values for each drug/bug combination has been determined according to EUCAST clinical breakpoints 
[46]. Protocol used is presented in box 2. 
 
Box 2: Vitek 2 analysis protocol for Gram-negative rods, as given by the manufacturer (bioMérieux). 
 
Manual AST was performed by the disk diffusion method on two samples due to uncertain Vitek 2 
results. Fresh colonies were suspended in a 0.45 % saline solution as described for the Vitek 2 sample 
preparation. A sterile cotton swab was used to spread the bacterial suspension in an even layer on a 
Mueller-Hinton (MH) agar plate (see recipe in appendix A). Three plates were prepared for each 
sample. Antibiotic disks were then applied to the inoculated MH-plates. These antibiotic disk panels 
are listed in table 3.1, and relative positions of the compounds are presented in figure 3.2. 
  
 
Vitek 2 analysis for Gram-negative rods 
1. Inoculate isolates on blood agar and incubate at 35 °C overnight. 
2. Suspend fresh colonies in 0.45 % saline solution (3.0 ml) in plastic tubes to a 
concentration of 0.5 – 0.63 McFarland1. 
3. Place bacterial suspension in a Vitek 2 rack, and place the AST-N209 card in an empty 
tube in the adjacent slot. Use one card for each isolate. 
4. Put the whole rack inside the Vitek 2 instrument for analysis. 
1Measured on a DEN-1 McFarland densitometer (Montebello Diagnostics, Oslo, Norway) 
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Table 3.1: Antibiotic disk panels used in manual AST of Enterobacteriaceae, routinely used in the Medical Microbiology 
Laboratory at Stavanger University Hospital. 
Panel 
Enterobacteriaceae  
(C) 
Enterobacteriaceae extended 
(D) 
ESBL 
 
A
n
ti
b
io
ti
c 
co
m
p
o
u
n
d
s 
Ampicillin 10 µg Cefuroxime 30 µg Ceftazidime/Clavulanic acid 
30 µg / 10 µg 
Trimethoprim/Sulfamethoxazole 
1.25µg  / 23.75 µg 
Gentamicin 10 µg Cefotaxime/Clavulanic acid 
30 µg / 10 µg 
Ciprofloxacin 5 µg 
 
Meropenem 10 µg Ceftazidime 30 µg 
Ceftazidime 10 µg Piperacillin / Tazobactam 
30 µg / 6 µg 
Cefotaxime 30 µg 
Cefotaxime 5 µg 
 
 Cefoxitin 30 µg 
Amoxicillin/Clavulanic acid  
20 µg / 10 µg 
 Ertapenem 10 µg 
 
An ESBL-phenotype and co-resistance to other relevant antibiotics were determined from the AST 
results. The following antibiotics were considered to define whether an ESBLA positive isolate was 
resistant to other relevant antibiotic groups (i.e. co-resistant): nitrofurantoin, trimethoprim 
/sulfamethoxazole, ciprofloxacin, gentamicin, and tobramycin. 
 
 
Figure 3.2: Manual AST setup. The three blue circles each represent one Mueller-Hinton agar-plate, and the white circles 
inside each represent antibiotic tablets. CTX = cefotaxime, CTX-Cl = cefotaxime / clavulanic acid, CIP = ciprofloxacin, SXT 
= trimethoprim / sulfamethoxazole, AMP = ampicillin, CAZ = ceftazidime, CAZ-Cl = ceftazidime / clavulanic acid, AMC = 
amoxicillin / clavulanic acid, CXM = cefuroxime, GEN = gentamicin, MEM = meropenem, TZP = piperacillin / tazobactam, 
FOX = cefoxitin, ETP = ertapenem.  
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3.5 DNA extraction 
Bacterial DNA was extracted by transferring a few colonies to 500 µl of sterile water in an Eppendorf 
tube. The suspension was then mixed well, and boiled at 100 °C for 10 minutes. After boiling, the 
suspensions were centrifuged at 13.000 x g for five minutes. The supernatant, containing bacterial 
DNA, was then transferred to a new tube and stored at 4 °C. 
3.6 Conventional PCR and gel electrophoresis 
 
Polymerase chain reaction (PCR) is a method which is used to amplify a specific gene of interest by 
the use of a thermocycler. It is based on three main steps, denaturation, annealing, and elongation of 
DNA. The denaturation step makes the DNA single stranded. Primers anneal to the single stranded 
DNA, and finally the polymerase incorporate new nucleotides that are complementary to the reference 
sequence. The cycle is repeated many times, which will make millions of copies of the original 
sequence. The enzyme Thermus aquaticus (Taq) polymerase is commonly used, as it tolerates high 
temperatures. 
One-directional gel electrophoresis is normally used to separate DNA fragments amplified by 
conventional PCR. DNA fragments move toward the positive pole of the electrophoresis chamber 
because of its negative charge, and is separated based on their size. Agarose is used to create the 
matrix needed for separation. Small pores in the gel are formed which allows small fragments to move 
fast, while larger fragments move slower. The size of the pores is varying depending on agarose 
concentration. 
3.6.1  16S rRNA PCR 
To confirm the presence of bacterial DNA, a PCR targeting the 16S rRNA gene was performed on all 
extracts, as previously described [55]. Primers, along with amplicon sizes, are listed in appendix A. 
Reagents used are listed in table 3.2. The PCR program is described in table 3.3. PCR products were 
visualized on an agarose gel (1.0 %, 110 V, 30 minutes). Positive controls are listed in appendix A. 
The “HotStarTaq Master Mix kit” (Qiagen, Hilden, Germany) was used. 
Table 3.2: 16S rRNA PCR reagents. 
Reagent Volume (per reaction) 
H2O 7.20 µl 
2x HotStarTaq Master Mix (Qiagen) 10.0 µl 
16S primer F (10 µM) 0.40 µl 
16S primer R (10 µM) 0.40 µl 
Template 2.0 µl 
Total 20.0 µl 
 
Table 3.3: 16S rRNA PCR program [55]. 
Cycles Temperature (°C) Time 
- 95 15 m 
32 
95 40 s 
58 60 s 
72 60 s 
- 72 10 m 
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3.6.2  ESBLA – PCRs 
All isolates were screened for the presence of blaCTX-M, blaTEM, and blaSHV genes by a PCR specifically 
targeting these genes, as previously described [81]. Primers are listed in table 3.7, PCR reagents in 
table 3.4, and PCR program in table 3.5. Detailed primer information is listed in appendix A. A 
subsequent gel electrophoresis was run to visualize the PCR products (1.0 % agarose gel, 110 V, 30 
minutes). Positive controls are listed in appendix A. 
Table 3.4: blaCTX-M, blaTEM and blaSHV PCR reagents. 
 Reagent Volume (per reaction) 
b
la
C
T
X
-M
 
H2O 6.0 µl 
2x HotStarTaq Master Mix (Qiagen) 10.0 µl 
blaCTX-M F (10 µM) 1.0 µl 
blaCTX-M R (10 µM) 1.0 µl 
Template 2.0 µl 
Total 20.0 µl 
b
la
S
H
V
 
&
 b
la
T
E
M
 
H2O 7.20 µl 
2x HotStarTaq Master Mix (Qiagen) 10.0 µl 
blaTem F/blaSHV F (10 µM) 0.40 µl 
blaTem R/blaSHV R (10 µM) 0.40 µl 
Template 2.0 µl 
Total 20.0 µl 
 
Table 3.5: blaCTX-M, blaTEM and blaSHV PCR programs [81]. 
 Cycles Temperature (°C) Time 
b
la
C
T
X
-M
 &
 
b
la
T
E
M
 
- 95 15 m 
35 
94 30 s 
50 30 s 
72 60 s 
- 72 10 m 
b
la
S
H
V
 
- 94 5 m 
35 
94 60 s 
58 30 s 
72 60 s 
- 72 5 m 
 
CTX-M group 1 real-time PCR (RT-PCR) (see 3.8) positive isolates were run on blaCTX-M group 1 
specific PCRs. Primers used are listed in table 3.7, detailed primer information is listed in appendix A. 
Two PCR reactions were run to cover the whole sequence, with subsequent sequencing. PCR 
programs were the same as for the blaSHV PCR described in table 3.5. Reagents are listed in table 3.6. 
Positive controls are listed in appendix A. 
Table 3.6: blaCTX-M group 1 specific PCR reagents. 
Reagent Volume (per reaction) 
H2O 6.80 µl 
2 x HotStarTaq MM (Qiagen) 10.0 µl 
F primer  0.60 µl 
R primer 0.60 µl 
Template 2.0 µl 
Total 20.0 µl 
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Table 3.7: Primers used for PCR of blaCTX-M, blaCTX-M  group 1, blaSHV and blaTEM genes. Detailed primer information is listed 
in appendix A. 
Gene blaCTX-M CTX-M group 1 blaSHV blaTEM 
 
PCR 
primers 
 
 
 
 
 
blaCTX-M F 
blaCTX-M R 
 
CTX-M-1 F 
Orf477 R 
ISEcp-tnpA1 F 
ISEcp-tnpA2 F 
ISEcp-tnpA3 F 
CTX-M-1 R 
 
blaSHV F 
blaSHV R 
blaTEM F 
blaTEM R 
 
3.6.3  PCR-based replicon typing 
The CTX-M-15 and SHV-5 group isolates were analysed by PCR-based replicon typing (PBRT) to 
determine the replicon types of CTX-M-15 and SHV-5 encoding plasmids.  
A commercially available PBRT kit was used (Diatheva, Fano PU, Italy) [22]. 
The kit is based on eight multiplex PCR reactions. In total, 25 primer pairs are used to detect the most 
common inc-types in Enterobacteriaceae (inc HI1, HI2, I1, I2, X1, X2, L/M, N, FIA, FIB, FIC, FII, 
FIIK, W, Y, P, A/C, T, K, U, R, B/O, HIB-M and FIB-M). The kit contains pre-made master mix for 
each multiplex PCR reaction, DNA polymerase, and positive controls.  
For each reaction, pre-made master mix (23.80 µl) was mixed with DNA polymerase (0.20 µl), after 
which the template was added (1.0 µl). Each PCR reaction was run under the same conditions (table 
3.8). 
Table 3.8: PRBT PCR-program, as given by the producer (Diatheva). 
Cycles Temperature (°C) Time 
- 95 10m 
 
25 
95 
60 
72 
60s 
30s 
60s 
- 72 5m 
 
Gel electrophoresis was run to visualize the amplicons. Loading dye (5.0 µl) was added directly to the 
PCR product, which was loaded into a 2.5 % agarose gel, along with a 100 bp plus ladder (Qiagen). 
The gel was run on 120 volt for 70 minutes. Visible bands were compared with the positive control 
and identified. 
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3.6.4  Capsular typing and virulence gene PCR 
Capsular typing and virulence gene detection was performed on the SHV-5 group isolates to detect the 
presence of selected capsule types or virulence genes. 
A multiplex PCR covering the K – types K1, K2, K5, K20, K54, and K57, as well as the virulence 
genes rmpA and wcaG have previously been described [83]. The PCR also contains a K. pneumoniae 
16S rRNA (Kpn 16S) primer set. 
A master mix was made with all the primers (listed in appendix A). PCR reagents are presented in 
table 3.9, and PCR program is described in table 3.10. The kit “Qiagen multiplex PCR kit” was used. 
PCR products were run on an agarose gel (1.5 %, 110 V for ~80 minutes). PCR controls are listed in 
appendix A. Negative controls included a non-virulent K. pneumoniae, and a standard contamination 
control with water. 
Table 3.9: Capsular typing and virulence gene multiplex PCR reagents [83]. 
Reagent Volume (per reaction) 
2 x Multiplex PCR master mix (Qiagen) 12.5 µl 
Primer (18) (10.0 µM) 9.0 µl 
H2O 1.5 µl 
Template 2.0 µl 
Total 25.0 µl 
 
Table 3.10: Capsular typing and virulence gene multiplex PCR program [83]. 
Cycles Temperature (°C) Time 
- 95 15 m 
35 
94 30 s 
58 90 s 
72 90 s 
- 72 10 m 
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3.6.5  Multilocus sequence typing 
The sequence types of the CTX-M-15 and SHV-5 group isolates were determined through multilocus 
sequence typing (MLST). 
MLST is a method developed for typing of many bacterial species. MLST for K. pneumoniae was 
developed by Diancourt et al., and is currently used the world over to determine the ST of isolates [32]. 
This is done by obtaining the DNA sequences of seven genes and by plotting the sequences into a 
database for comparison (http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html). The database will 
report allele numbers for each gene, and the combination of the allele numbers gives the sequence type. 
Seven genes are PCR-amplified and sequenced; all of which are housekeeping genes in K. 
pneumoniae: rpoB (β-subunit of RNA polymerase B), gapA (glyceraldehyde-3-phosphate 
dehydrogenase), mdh (malate dehydrogenase), pgi (phosphoglucose isomerase), phoE (phosphoporine 
E), infB (translation initiation factor 2), and tonB (periplasmic energy transducer). 
A Hot Star Taq Master Mix kit was used (Qiagen) with the same primer concentrations as the blaCTX-M 
PCR described under section 3.6.2. PCR program is listed in table 3.11, and primers are listed in 
appendix A. All genes were amplified at an annealing temperature of 50 °C, except gapA (60 °C) and 
tonB (45 °C).  
Table 3.11: MLST PCR program as given by the Pasteur website. The original PCR program settings are listed in 
parenthesis (changed due to different polymerase chemistry). 
Cycles Temperature (°C) Time 
- 95 (94) 15m (2m) 
35 
94 20s 
30s 
30s 
45, 50, 60 
72 
- 72 5m 
 
Sequencing was performed as described in section 3.7. The sequences were manually inspected by 
using SeqScape version 2.5 (Applied Biosystems, Foster City, CA, USA) software. Reference 
sequences were given at the Pasteur website (link above). 
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3.7 Sanger sequencing 
 
The blaCTX-M group 1, blaTEM and blaSHV genes were typed by sequencing of amplified PCR products to 
determine the ESBLA –encoding gene type. 
Sanger sequencing is commonly used when sequencing smaller DNA fragments, for example genes or 
gene cassettes. The technique is based on the use of dideoxynucleotides (ddNTP’s), which have no 
hydroxyl group on the 3’ carbon atom in the sugar. Because the hydroxyl group is lacking, the 
polymerase cannot elongate the DNA fragment further, effectively terminating the polymerization. 
Consequently, the DNA fragments will become different sizes, depending on where the terminator 
base is incorporated. These ddNTP’s are added in the reaction solution, along with the template DNA 
and radioactively labelled primers. The reaction is run on a thermal cycler, and after completion, the 
DNA fragments are released from the template by denaturing at 95 °C. The sample tube now holds a 
collection of many different labelled DNA fragments, along with the single-strands of the template 
DNA [76]. The fragments are then analysed in a capillary electrophoresis instrument to determine the 
correct nucleotide sequence. The instrument uses gel electrophoresis to separate the fragments by size 
and thus read the correct nucleotide sequence by laser detection.  
The blaCTX-M group 1 genes were sequenced first, then the blaSHV. If no ESBL-encoding variants were 
found, blaTEM was sequenced (if the isolate was positive for blaTEM). Primers used for sequencing are 
listed in table 3.12. Detailed primer information is listed in appendix A. The BigDye Terminator v1.1 
sequencing kit (Applied Biosystems) was used. PCR products from the blaCTX-M, blaTEM and blaSHV 
PCRs, described under section 3.6.2, were sequenced. 
Table 3.12: Primers used for sequencing of blaCTX-M group 1, blaSHV and blaTEM genes. 
Gene blaCTX-M group 1 blaSHV blaTEM 
 
 
Sequencing 
primers 
 
 
CTX-M-1 F 
Orf477 R 
ISEcp-tnpA2 F 
blaSHV F 
blaSHV R 
Core SHV F 
Core SHV R 
blaTEM F 
blaTEM R 
TEM F extra 
TEM R extra 
 
Prior to sequencing, residual primers and nucleotides were removed from the PCR product by 
treatment with ExoSAP-IT (Affymetrix, Mercury Park, UK). Protocol used is presented in box 3. The 
sequencing reaction reagents are listed in table 3.13, and PCR program is listed in table 3.14, taken 
from the “BigDye Terminator v1.1 Cycle Sequencing Kit Protocol” (found at lifetechnologies.com). 
 
Box 3: ExoSAP-IT protocol, as given by the manufacturer (Affymetrix). 
 
ExoSAP-IT 
1. Add ExoSAP-IT (2.0 µl) to an aliquot of the PCR product (5.0 µl). 
2. Incubate at 37 °C for 15 minutes. 
3. Incubate at 80 °C for 15 minutes. 
4. Add purified PCR product (2.0 µl) to a sequencing master mix (18.0 µl) (table 3.13). 
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Table 3.13: Sequencing reaction reagents, concentrations and volumes. This setup was used for all sequencing reactions in 
this study, regardless of gene analyzed. Source: lifetechnologies.com 
Reagent Stock concentration Volume( per reaction) 
Water  12.68 µl 
BigDye v. 1.1 (Applied Biosystems) 2.5 x 2.0 µl 
BigDye buffer (Applied Biosystems) 5 x 3.0 µl 
Primer 10 pmol/µl 0.32 µl 
PCR product  2.0 µl 
Total  20.0 µl 
 
Table 3.14: Sequencing reaction PCR program used for all genes sequenced in this study. Source: lifetechnologies.com. 
Cycles Temperature Time 
1 95 60 s 
25 
95 10 s 
54 5 s 
60 4 m 
 
The sequences were cleaned by the ZR DNA Sequencing Clean-up Kit (Zymo Research, Irvine, USA). 
Protocol used is presented in box 4. 
 
Box 4: ZR DNA sequencing clean-up kit protocol, as given by the manufacturer (Zymo Research). 
The sequences were analysed on a 3130 Genetic analyser (Applied Biosystems).  
The blaCTX-M group 1, blaTEM and blaSHV sequences obtained were converted to protein sequences using 
the ExPASy translate tool (http://web.expasy.org/translate/). Possible amino acid changes were 
detected by comparing the protein sequences with sequences published in the Lahey database, and 
type of enzyme was determined. 
MLST DNA sequences were directly plotted into the Pasteur database for identification of allele 
numbers. 
  
 
ZR DNA Sequencing Clean-up 
1. Add sequencing binding buffer (240.0 µl) to the sequencing product and transfer to a 
Zymo-Spin column placed in a collection tube.  
2. Centrifuge at 13.000 rpm for 30 seconds, discard flow-through.  
3. Add sequencing wash buffer (300.0 µl) to the column. 
4. Centrifuge at 13.000 rpm for 30 seconds, discard flow-through.  
5. Place column in a 1.5 ml Eppendorf tube.  
6. Add PCR-grade water (20.0 µl) directly to the filter in the column. 
7. Centrifuge at 13.000 rpm for 30 seconds to elute sequencing product. 
8. Sequencing product now ready to be analysed. 
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3.8 Real-Time PCR 
 
To determine the CTX-M group, a group-specific RT – PCR assay was performed on all blaCTX-M 
positive isolates, as previously described [11]. 
Real-time PCR (RT-PCR) is a method where the amplification of PCR product is visualized in real 
time, by using a fluorescent probe. There are many probe systems in use, like TaqMan and FRET 
probes. In this study, TaqMan probes were used. These probes are fitted with one reporter, which is 
the fluorescent molecule, and one quencher, which inhibits the fluorescence. The probe is designed to 
anneal somewhere between the primers. When the polymerase polymerize along the DNA strand, the 
probe will break apart and release the quencher from the reporter, allowing fluorescence. Fluorescence 
increase when more PCR product is produced, resulting in a sigmoid graph in the software [42]. 
The RT – PCR was carried out on the Viia7 system (Applied Biosystems). The primers and probes 
used for this RT-PCR were specifically designed for the CTX-M-1 and CTX-M-9 groups. RT-PCR 
reagents are listed in table 3.15. Probes are listed in table 3.16, and primers are listed in appendix A. 
PCR program is presented in table 3.17. Positive controls are listed in appendix A. 
Table 3.15: RT-PCR reagents for CTX-M group specific analysis. Modified from Birkett et al. 2006 [11]. 
Reagent Volume (per reaction) 
H2O 9.56 µl 
4x TaqMan Fast Virus Master Mix (Qiagen) 5.0 µl 
blaCTX-M F (100 µM) 0.18 µl 
blaCTX-M R (100 µM) 0.18 µl 
CTX-M group specific probe 0.08 µl 
Template 5.0 µl 
Total 20.0 µl 
 
Table 3.16: RT-PCR probes for the detection of CTX-M groups. Modified from Birkett et al. 2006 [11]. 
Group Probe sequence Reporter/Quencher 
CTX-M-1 5’- CCC GAC AGC TGG GAG ACG AAA CGT - 3’ FAM-TAMRA 
CTX-M-9 5’- CTG GAT CGC ACT GAA CCT ACG CTG A - 3’ VIC-TAMRA 
 
Table 3.17: RT-PCR program for CTX-M group identification on the Viia7 system. 
Stage Cycles Temperature (°C) Time 
Pre-read - 50 30 s 
Hold - 
50 5 m 
95 20 s 
PCR 40 
95 3 s 
60 30 s 
Post-read - 50 30 s 
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3.9 Pulsed field gel electrophoresis 
 
All isolates were subjected to pulsed field gel electrophoresis (PFGE) for genotyping. 
PFGE is a method used in many microbiology labs to determine whether the isolates in question are 
clonally related. The method is derived from the classic gel electrophoresis, which separates DNA-
fragments on the basis of their size and therefore also their charge. However, in conventional gel 
electrophoresis there is only one source of current, and the flow is unidirectional. In PFGE, the current 
usually flows from three different sources, with an angle of 120 degrees between each electrode. These 
electrodes are switched on and off based on timers which are specified by the user. However, the 
unidirectional current is always flowing [23]. 
PFGE produces better separation compared to conventional gel electrophoresis. Plugs with suspended, 
lysed cells are treated with a restriction enzyme that cut DNA at specific recognition sites unique to 
the enzyme. This generates DNA fragments of various sizes, depending on the genome of the microbe 
analysed. Each isolate will thus produce a specific band pattern on the gel. 
An enzyme commonly used for K. pneumoniae PFGE is XbaI, which has the following recognition 
site [2]:  
        ▼ 
5’ – T CTAGA - 3’ 
3’ – AGATC T – 5’ 
       ▲ 
 
Protocol used is presented in box 5. The isolates were analysed using the standard operating procedure 
for PulseNet PFGE of various Enterobacteriaceae [24]. All solutions used in the PFGE protocol are 
listed in section 3.12, table 3.26. 
  
24 
 
 
Box 5: XbaI PFGE protocol [24]. 
The gel was depicted in ChemiDoc XRS+ (BioRad), and the image was analysed in Bionumerics 
(Applied Maths, St-Martens-Latem, Belgium). A phylogenetic tree was devised from the band 
relations by using the Dice coefficient with 1.5 % position tolerance. Clustering analysis was 
performed by the unweighted pair group method with arithmetic mean (UPGMA). Isolates above the 
80 % similarity mark were considered closely related. 
  
 
XbaI – PFGE 
1. Inoculate 10 isolates on blood agar and incubate for 20-24 hours at 35 °C. 
2. Suspend bacterial colonies in cell suspension buffer (2.0 ml) at a concentration of 3-4 
McFarland. 
3. Mix the cell suspension (200.0 µl) with 20 mg/ml Proteinase K (10.0 µl), then add 1% 
SeaKem Gold agarose
1
 (200.0 µl), mix briefly and transfer to PFGE plug moulds. 
4. After solidification, lyse the plugs at 55 °C for 1.5 – 2.0 hours with agitation in a cell lysis 
buffer (5.0 ml) with added Proteinase K (25.0 µl). 
5. Wash plugs twice with pre-heated dH2O (55 °C, 10 - 15 ml) for 10-15 minutes at 55 °C, 
then four times with pre-heated TE-buffer (55 °C, 10-15 ml) for 10 – 15 minutes at 55 °C. 
6. Store washed plugs in TE-buffer at 4 °C. 
7. Wash plugs twice with pre-heated TE-buffer after storage, before use. 
8. Cut 1.5 mm pieces of the plugs and incubate at room temperature for 10 – 15 minutes in 
1:10 diluted XbaI
2
 restriction buffer (200.0 µl). 
9. Incubate plugs at 37 °C for 1.5 – 2.0 hours in XbaI restriction enzyme2 mix (table 3.18). 
10. Prepare a 1.0 % SeaKem Gold agarose gel and equilibrate at 55 °C. 
11. Fill the electrophoresis chamber with 0.5 x TBE buffer (2.0 – 2.2 L). Calibrate pump to 
pump one litre per minute, and set temperature to 14 °C. 
12. Incubate the plugs in 0.5 x TBE buffer (200.0 µl) for five minutes at room temperature. 
13. Mount the plugs on the gel comb and fix with agarose. Pour the gel, remove the comb and 
add lambda ladder
2
. 
14. Seal wells with agarose and run the gel with the settings presented in table 3.19. 
15. Dye gel with ethidium bromide solution for 20-30 minutes, and then de-stain with dH2O 
for 60 – 90 minutes with water change every 20 minutes.  
16. Depict gel. 
 
1BioRad, Oslo, Norway 
2New England Biolabs, Ipswich, UK 
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Table 3.18: XbaI restriction enzyme mix used in PFGE of K. pneumoniae, in accordance with the PulseNet central Standard 
Operating Procedure for PulseNet PFGE of various Enterobacteriaceae. BSA = bovine serum albumin. 
Reagent Volume (per sample) 
dH2O 173.0 µl 
Restriction enzyme buffer (10x) 20.0 µl 
BSA (10 mg/ml) 2.0 µl 
XbaI (10 U/µl) 5.0 µl 
Total 200 µl 
 
Table 3.19: PFGE program parameters for K. pneumoniae used at Stavanger University Hospital, provided by PulseNet 
Central for various Enterobacteriaceae.  
Parameter Value 
Pulse Time 1 – 20 s 
Total run time 21 H 
Voltage 6.0 v/cm (200 V) 
Angle 120° 
Buffer temperature 14 °C 
Buffer 0.5 x TBE 
 
Some isolates produced smears on the PFGE gels. An addition of thiourea (2.20 ml of a 300 mM 
solution, with a final concentration of 300 µM) into the running buffer (2.20 L) prompted the isolates 
to produce visible bands, as previously described [78]. 
 
3.10 Plasmid detection 
 
The CTX-M-15 and SHV-5 group isolates were treated with the enzyme S1-nuclease and subsequently 
subjected to PFGE to detect plasmids present in these isolates. 
The detection of plasmids and their size using S1-PFGE has previously been described [7].The method 
is based on the enzyme S1-nuclease, which was isolated from the mould Aspergillus orzyae. The 
enzyme attacks single-stranded regions, and for plasmids that are negatively supercoiled, this will lead 
to a linearization of the plasmid due to the nicking action of the enzyme and loss of supercoiling. By 
linearizing plasmids, one can separate them by size with PFGE, and thus find out how many plasmids 
an isolate carry and how big they are. 
Protocol used is presented in box 6. All solutions used in the S1-PFGE protocol are listed in section 
3.12, table 3.27. 
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Box 6: S1-nuclease PFGE protocol, modified from Naseer et al. 2009 [62]. Additional references: [7, 56, 74]. 
Table 3.20: S1-nuclease enzyme mix used for S1-PFGE. The volume of enzyme depends on the unit amount per µl of the 
stock solution. 
Reagent Volume 
S1-nuclease buffer (10x) (Takara) 12.5 µl 
S1-nuclease (180 U/µl) (Takara) 0.23 µl 
dH2O 112.26 µl 
Total 125 µl 
 
Table 3.21: PFGE parameters used for S1-PFGE. The parameters are designed to effectively separate smaller DNA 
fragments. Modified protocol from Naseer et al. 2009 [62]. 
Parameter Value 
Pulse Time 1-20 s 
Run Time 15 H 
Voltage 6.0 v/cm (200 V) 
Angle 120° 
Buffer temperature 15 °C 
Buffer 0.5 x TBE 
 
The plasmids were sized using the ChemiDoc XRS+ Image Lab software (BioRad).  
The isolates that produced smears in PFGE also did in S1-PFGE. The addition of thiourea as described 
in section 3.9 solved the issue.  
 
 
S1-PFGE 
1. Cut 1.5 mm slices from the plugs and wash twice in TE-buffer (1.0 ml) at room 
temperature for 30 minutes. 
2. Incubate plugs with Tris-HCl (1.0 ml) for 30 minutes at room temperature. 
3. Wash plugs with 1:10 diluted S1-nuclease1 buffer (125.0 µl) for 30 minutes. 
4. Incubate plugs with S1-nuclease1 mix (table 3.20) at 37 °C for 25 minutes. 
5. Inactivate the enzyme with 20mM EDTA (100.0 µl) and incubate for 2-5 minutes. 
6. Wash plugs twice with cold TE-buffer (1.0 ml) for 30 minutes. 
7. Prepare a 1.0 % agarose gel with Pulsed Field certified agarose2 and 0.5 x TBE buffer 
and equilibrate to 55 °C. 
8. Fix the plugs and pour the gel in a similar manner as described in box 5. 
9. Add low-range PFG marker3 as ladder. 
10. Run the gel with the parameters listed in table 3.21. 
1Takara, Saint-Germain-en-Laye, France 
2BioRad 
3New England Biolabs 
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3.11 Southern blot hybridization 
 
The CTX-M-15 and SHV-5 group isolates were analysed by Southern blot and hybridization to 
localize the ESBLA –encoding gene and detect the replicon type of the plasmid. 
Southern blot is a classic molecular technique that is based on the transfer of DNA from a gel to a 
membrane by capillary forces, vacuum transfer or other methods. Southern blot was developed by 
Edwin Southern in 1975, as a way to detect specific nucleotide sequences in separated and digested 
DNA fragments [16]. The gel is pre-treated with HCl to depurinate the DNA, then with NaOH to 
denature. This is done to ease transfer of DNA to the membrane. The membrane is then hybridized 
with a probe, which can be visualized in a variety of ways, including colorimetry, fluorescence, or 
radioactive labelling. Various applications of Southern blot have been developed. Specific probes can 
easily be made by PCR, which makes this method especially useful.  
Probes for Southern blot hybridization are quick and easy to synthesize to date, due to effective PCR 
methods. The probe is a DNA sequence that complements the gene sequence of interest, labelled with 
DIG-dUTP (digoxigenin-11-2’-deoxy-uridine-5’-triphosphate), which is incorporated in the PCR 
reaction (figure 3.3) [43]. 
 
Figure 3.3: DIG-dUTP PCR labeling reaction. The DIG-dUTP is incorporated by the polymerase due to the deoxy-uridine-
triphosphate end of the molecule, which is used as a nucleotide by the polymerase. Source: lifescience.roche.com, used with 
permission from Roche Diagnostics Norway. 
The DIG-High Prime DNA Labelling and Detection Starter Kit I (Roche Diagnostics, Mannheim, 
Germany), utilizes colorimetric detection to visualize bands on the membrane. Antibodies, specifically 
fragments of polyclonal anti-digoxigenin, will bind to the DIG-labelled probe which has been 
hybridized to the fixated nucleic acids on the membrane. A blocking solution blocks any unwanted 
bonding of these antibodies. The antibodies are coupled with an alkaline phosphatase, which will 
catalyse the colour reaction needed for colorimetric detection. The colour substrate solution contains 
BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate / nitroblue tetrazolium chloride) which will be 
dephosphorylated by the alkaline phosphatase added previously. The following redox reaction that 
takes place will produce a purple precipitate at the site of enzyme activity, and will form the bands on 
the membrane [43]. 
In this study, Southern blot was used to link plasmids identified with S1-PFGE with the replicon type 
and ESBLA-gene previously found, by the use of a specific probe which targets the blaCTX-M and 
blaSHV-genes. Also, an FIIK-probe was made to determine if the plasmid was carrying an FIIK-replicon 
along with the ESBLA-gene. The DIG-High Prime DNA Labelling and Detection Starter Kit I (Roche 
Diagnostics) was used to make the probes and the post-transfer and -hybridization steps. All solutions 
used in the Southern blot protocol are listed in section 3.12, table 3.28. 
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3.11.1  Synthesis of hybridization probes 
 
PCR and cleanup 
One blaCTX-M, one blaSHV and one IncFIIK probe was made. A PCR was performed on these genes as 
described under section 3.6.2. (The IncFIIK primers (appendix A) and PCR program (table 3.22) was 
found in Villa et al. 2010 [86]). The IncFIIK PCR used the same reagents and concentrations as the 
blaCTX-M PCR listed in section 3.6.2. 
Table 3.22: IncFIIK PCR program. The original PCR program settings are in parentheses [86]. 
Cycles Temperature (°C) Time 
- 95 (94) 15 m (5 m) 
30 
94 60 s 
60 30 s 
72 60 s 
- 72 5 m 
 
The PCR product was then purified by the QIAquick PCR purification kit (Quiagen), protocol 
presented in box 7. 
 
Box 7: QIAquick PCR purification kit protocol, as given by the manufacturer (Qiagen). 
 
Following the purification, the concentration of the PCR product needed to be ascertained. This was 
done with the Qubit assay (Invitrogen, Thermo Scientific, Massachusetts, USA), presented in box 8. 
 
QIAquick PCR purification kit 
1. Add five volumes buffer PB to one volume PCR product and transfer to a QIAquick spin 
column with a collection tube.  
2. Centrifuge at 13.000 rpm for 30-60 seconds, and discard flow-through. 
3. Add buffer PE (750.0 µl) to the spin column. 
4. Centrifuge at 13.000 rpm for 30-60 seconds. 
5. Discard flow-through and centrifuge at 13.000 rpm for 30-60 seconds to remove residual 
ethanol. 
6. Place column in clean 1.5 ml tube and add buffer EB (30.0 µl) directly onto the filter. 
7. Incubate one minute, then centrifuge at 13.000 rpm for 30-60 seconds, to elute the DNA. 
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Box 8: Qubit assay protocol, as given by the manufacturer (Invitrogen). 
The DNA was now ready to be labelled with DIG-dNTP, protocol presented in box 9. 
 
Box 9: Template labelling protocol, from the DIG-High Prime DNA Labelling and Detection Starter Kit I (Roche). 
 
Table 3.23: DIG-High Prime labelling reaction yield after one and 20 hours. Optimal template amount was deemed to start at 
1000 ng, with a total yield of 2300 ng after 20 hours (as stated by the manufacturer). 
Template DNA 1 Hour 20 Hours 
10 ng 45 ng 600 ng 
30 ng 130 ng 1050 ng 
100 ng 270 ng 1500 ng 
300 ng 450 ng 2000 ng 
1000 ng 850 ng 2300 ng 
3000 ng 1350 ng 2650 ng 
 
Prior to utilization, the final concentration of the probes had to be calculated, and their effectiveness 
had to be ascertained. The probes and a DIG-labelled control were diluted to a concentration of 1 ng/µl, 
and a series of dilutions were made (table 3.24).  
  
 
Qubit assay 
1. Prepare one assay tube per sample and two tubes for the standards. 
2. Dilute the Qubit reagent 1:200 in Qubit buffer. Prepare approximately 200 µl per tube. 
3. Dilute each standard (broad range) (10.0 µl) in the working solution (190 µl). 
4. Dilute samples (2.0 µl) in the working solution (198 µl).  
5. Vortex all tubes and incubate for two minutes at room temperature. 
6. Analyse on the Qubit 2.0 fluorometer, following machine instructions. 
 
Template labelling 
1. Dilute one microgram of template with water, to a total volume of 16.0 µl. 
2. Denature the template by boiling at 100 °C for 10 minutes, then rapidly cool. 
3. Add DIG-High Prime (4.0 µl) to the template, mix gently, and incubate at 37 °C for 20 
hours. 
4. Heat the sample to 65 °C for 10 minutes to stop the reaction. 
5. Calculate reaction yield from table 3.23. 
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Table 3.24: Dilution series for testing of probes made for Southern blot. The column «DNA (µl)» describes how many µl of 
the probe and the control that are used, and the column «from tube...» refers to which tube the volume is taken from. 
ID DNA (µl) From tube… DNA dilution buffer (µl) Dilution End 
concentration 
1 - Diluted original - - 1 ng/µl 
2 2 1 198 1:100 10 pg/µl 
3 15 2 35 1:3.3 3 pg/µl 
4 5 2 45 1:10 1 pg/µl 
5 5 3 45 1:10 0.3 pg/µl 
6 5 4 45 1:10 0.1 pg/µl 
7 5 5 45 1:10 0.03 pg/µl 
8 5 6 45 1:10 0.01 pg/µl 
9 0 - 50 - 0 
 
The serially diluted probes were then fixated to a membrane and detected, protocol presented in box 
10. 
 
Box 10: Probe fixation and detection protocol, from the DIG-High Prime DNA Labelling and Detection Starter Kit I (Roche). 
 
The colour intensity of the probes was compared to the control DNA, and the approximate 
concentration was calculated (table 3.25). 
 
Table 3.25: Calculated probe concentrations for all three probes used in the southern blot analysis. The concentrations are 
approximate values. 
Probe Concentration 
blaCTX-M 37.5 ng/ml 
blaSHV 7.6 ng/ml 
IncFIIK 25 ng/ml 
 
 
Probe fixation and detection 
1. Add diluted probes (1.0 µl) to a marked, positively charged nylon membrane1 and fixate at 
100 °C for two hours. 
2. Incubate membrane in maleic acid buffer (30.0 ml) at room temperature for two minutes. 
3. Incubate membrane in blocking solution (10.0 ml) for 30 minutes with agitation. 
4. Incubate membrane in antibody solution (10.0 ml) for 30 minutes with agitation. 
5. Wash membrane twice with washing buffer (10.0 ml) for 15 minutes. 
6. Incubate membrane in detection buffer (10.0 ml) for 2-5 minutes. 
7. Incubate in the dark with colour substrate solution (2.0 ml) for approximately 30 minutes, 
or until desired colour intensity has been reached. 
8. Wash membrane with dH2O to stop the reaction. 
1Hybond N+, Amersham 
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3.11.2  Transfer and detection 
 
Pre-treatment and transfer 
A vacuum blotting system was used for the transfer of S1-PFGE gel to a positively charged membrane 
by the use of a vacuum Blotter model 785 (Bio Rad), protocol presented in box 11. 
 
Box 11: Gel pre-treatment and transfer protocol, as given by the Vacuum blotter manufacturer (BioRad). 
 
Hybridization and immunological detection 
The membrane was now ready for hybridization and subsequent detection. Protocol presented in box 
12.  
 
Pre-treatment and transfer 
1. Wash gel in pure water, then depurinate with 0.25 N HCl for 30 minutes with agitation.  
2. Wash gel twice in pure water, then denature with 0.5 N NaOH for 40 minutes. 
3. Neutralize with neutralizing buffer for 30 minutes. 
4. Wash gel with 10 x SSC buffer. 
5. Moisten positively charged nylon membrane and filter paper in dH2O and 10 x SSC 
buffer. 
6. Place filter paper and membrane on vacuum membrane. Assemble the rest of the vacuum 
blotter. 
7. Place gel on top of membrane, remove any bubbles. 
8. Calibrate vacuum pump to 10 in Hg. Check system for leaks. 
9. Add 10 x SSC buffers (1.0 – 1.5 L) to the transfer chamber. 
10. Transfer for 90 minutes. 
11. Wash membrane in 2 x SSC buffer, then air dry. 
12. Fixate overnight at 100 °C. 
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Box 12: Hybridization and immunological detection protocol, from the DIG-High Prime DNA Labelling and Detection 
Starter Kit I (Roche). 
 
Bands were detected and compared with the S1-gel for identification. 
  
 
Hybridization and immunological detection 
1. Put fixated membrane inside a hybridization tube with the nucleic acids facing the middle 
of the tube.  
2. Add pre-heated (40 °C) DIG Easy Hyb buffer (40.0 ml) to the tube and pre-incubate 
membrane for 30 minutes with rotation. 
3. Denature DIG-labelled probe by boiling for five minutes, then cool. Add denatured probe 
to pre-heated (40 °C) DIG Easy Hyb buffer to a final concentration of 25 ng/ml 
(concentration depends on the effectivity of the probe). 
4. Add probe mix to the tube and incubate at 40 °C overnight with rotation. 
5. The DIG Easy Hyb buffers may be re-used several times. Simply freeze the solutions 
between each use, and denature the probe at 68 °C for 10 minutes prior to hybridization. 
6. Wash membrane in stringency wash buffer twice at room temperature for five minutes 
with agitation. Wash again with pre-heated (68 °C) stringency wash buffer twice at 
68 °C for 15 minutes with agitation. 
7. Wash membrane in washing buffer for 1 – 5 minutes. 
8. Incubate membrane with blocking solution (200.0 ml) for 30 minutes. 
9. Incubate membrane with antibody solution (60.0 ml) for 30 minutes. 
10. Wash membrane twice with washing buffer (200.0 ml) for 15 minutes. 
11. Stabilize with detection buffer (60.0 ml) for 2 – 5 minutes. 
12. Incubate in the dark with colour substrate solution (10.0 – 20.0 ml) until desired colour 
intensity is reached (30 minutes – 16 hours). 
13. Stop the reaction by washing with dH2O. 
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3.12 Solutions 
 
Table 3.26: Reagents used for XbaI-PFGE. 
Solution Contents Origin 
TE-buffer 10 mM Tris, 1 mM EDTA, pH 8.0 In-house 
Cell suspension buffer 
 
100 mM Tris, 100 mM EDTA, pH 
8.0 
In-house 
Cell lysis buffer 
 
50 mM Tris, 50 mM EDTA, pH 
8.0, 1% Sarcosyl 
 
In-house 
 
Ethidium bromide solution 
 
1.0 ng / ml Ethidium bromide In-house 
 
 
Table 3.27: Reagents used for S1-PFGE. 
Solution Contents Origin 
TE-buffer 10 mM Tris-HCl, 0.1 mM EDTA, 
pH 8.0 
 
In-house 
Tris-HCl 1.0 M Tris-HCl, pH 7.5 
 
 
In-house 
EDTA 20 mM EDTA 
 
In-house 
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Table 3.28: Reagents used for Southern blot and hybridization. 
Solution Contents Origin 
Pure water 
 
Filtered dH2O 
 
In-house 
Depurination solution 
 
0.25 N HCl 
 
In-house 
Denaturation solution 
 
0.5 N NaOH 
 
In-house 
Neutralizing buffer 1 M Tris-HCl, 1.5 M NaCl 
 
Sigma Aldrich, Oslo, Norway 
 
20x SSC buffer 
3 M NaCl, 300 mM trisodium 
citrate, pH 7.0 
 
Sigma Aldrich 
 
Stringency wash 
2x SSC (Sigma Aldrich), 0.1 % 
SDS (Sigma Aldrich) 
 
In-house 
 
10 x Washing buffer 
0.1 M maleic acid, 0.15 M NaCl, 
0.3 % (v/v) Tween 20, pH 7.5 
 
DIG Wash and Block buffer set 
 
Detection buffer 
0.1 M Tris-HCl, 0.1 M NaCl, pH 
9.5 
 
In-house 
 
Maleic acid buffer 
0.1 M Maleic acid, 0.15 M NaCl, 
pH 7.5 
 
DIG Wash and Block buffer set 
 
Dig Easy Hyb buffer Urea* 
 
DIG High Prime DNA Labelling 
and Detection Starter Kit I 
 
Blocking solution Pre-treated casein* 
 
DIG High Prime DNA Labelling 
and Detection Starter Kit I 
 
Antibody solution 
Polyclonal sheep anti-DIG 
antibodies + alkaline phosphatase* 
 
DIG High Prime DNA Labelling 
and Detection Starter Kit I 
 
Colour substrate solution BCIP/NBT* 
 
DIG High Prime DNA Labelling 
and Detection Starter Kit I 
 
DNA dilution buffer 
50 µg/ml fish sperm DNA in 10 
mM Tris-HCl, 1 mM EDTA, pH 8 
 
 
DIG High Prime DNA Labelling 
and Detection Starter Kit I 
 
 
*Concentrations not given by the manufacturer 
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4. Results 
 
4.1 Species identification and phenotypical analysis 
 
To confirm species identification and ESBLA – production selected isolates (n = 58) were inoculated 
on chromogenic ESBL medium and modified MacConkey medium with a cefotaxime disk. In total, 49 
isolates were putative ESBLA – producing K. pneumoniae and included for further analysis. 
The 49 isolates were identified by MALDI-TOF as K. pneumoniae subsp. pneumoniae, with an 
average score of 2.29 ± 0.066. AST by Vitek 2 was successful on all isolates, except two, where 
manual susceptibility testing was performed. Detailed results are listed in appendix B. Co-resistance 
profiles are presented in figure 4.4. 
 
4.2 Enzyme characterization 
 
The included isolates were screened for the ESBLA-genes blaCTX-M, blaTEM and blaSHV. Twenty-six 
were positive for blaCTX-M, 44 positive for blaSHV, and 35 positive for blaTEM (table 4.1). Of the 26 
blaCTX-M positive isolates, 22 were categorized as blaCTX-M group 1, and two as blaCTX-M group 9. Two 
isolates could not be typed into a specific CTX-M group. 
ESBLA – encoding genes were further typed through sequencing. The ESBL genes found are as 
follows: blaCTX-M-15 (n = 20), blaCTX-M-3 (n = 1), blaSHV-12 (n = 5), blaSHV-2 (n = 1), blaSHV-27 (n = 1), 
blaSHV-2A (n = 3) and blaSHV-5 (n = 13). The CTX-M – encoding gene could not be typed in five isolates. 
ESBLA – encoding genes for each isolate are listed in table 4.1. One TEM – encoding gene was 
sequenced, and was found to be a non-ESBLA – encoding gene.  
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Table 4.1: Screening for ESBLA – encoding genes by PCR and sequencing. ESBLA – encoding genes are listed in red (as 
found in the Lahey database). 
ID 
PCR Sequencing 
CTX-M TEM SHV CTX-M TEM SHV 
1a - + + - * SHV-5 
1b - + + - * SHV-5 
2 + - + UT - SHV-11 
3 - + + - * SHV-12 
4 - + + - * SHV-5 
5 + - - UT - - 
6 - - + - - SHV-5 
7 - - + - - SHV-5 
8 + + - UT * - 
9 - - + - - SHV-11 
10 + + + CTX-M-15 * SHV-1 
11 - + + - * SHV-5 
12 - + + - * SHV-5 
13 + + + CTX-M-15 * SHV-52 
14 + + + CTX-M-15 * SHV-11 
15 - + + - * SHV-5 
16 + - + CTX-M-15 - SHV-1 
17 + + + CTX-M-15 * SHV-11 
18 + + + CTX-M-15 * SHV-11 
19 + + + CTX-M-15 * SHV-52 
20a + + + CTX-M-15 * SHV-11 
20b + + + CTX-M-15 * SHV-11 
22 + + + CTX-M-15 * SHV-11 
23 - - + - - SHV-2A 
25 + + + CTX-M-15 * SHV-27 
28 + - + UT - SHV-11 
29 + + + CTX-M-15 * SHV-11 
32 + + + CTX-M-15 * SHV-11 
33 + - + UT - SHV-1 
34 - - + - - SHV-5 
35 + + + CTX-M-15 * SHV-2A 
36 - + + - * SHV-5 
37 + + + CTX-M-15 * SHV-1 
38 - - + - - SHV-12 
39 - + + - * SHV-2 
40 + + + CTX-M-15 * SHV-1 
42 - + + - * SHV-5 
43 - + + - TEM-57 SHV-33 
44 - - + - - SHV-12 
45 + + - CTX-M-15 * - 
46  + + - * SHV-5 
47 + + + CTX-M-15 * SHV-11 
48 + + + CTX-M-15 * SHV-32 
51 - - + - - SHV-12 
53 - + + - * SHV-12 
54 - + + - * SHV-5 
55 + + - CTX-M-15 * - 
56 + + - CTX-M-3 * - 
57 - - + - - SHV-2A 
 
UT = untypeable. * = Not sequenced. 
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4.3 Determination of clonal relatedness 
 
4.3.1 PFGE 
All isolates were subjected to XbaI – PFGE for detection of clonal relatedness. Band patterns were 
analysed in Bionumerics, and a phylogenetic tree was devised from the band relations (figure 4.4). In 
general, two clones were identified. Some similarity between some of the isolates was detected. Six 
nodes were found above the 80 % similarity mark. All SHV-5 group isolates grouped at around 88 %. 
Isolate 29 and 34 grouped at 89 %, 20a and 20b at 90 %, 17 and 18 at 100 %, 13 and 19 at 92 %, and 
51 and 57 at 84 % (figure 4.4). 
4.3.2 MLST 
To further characterize the isolates, the sequence types of the CTX-M-15 group and the SHV-5 group 
isolates were identified by MLST. All isolates were successfully typed. The following STs were 
identified: ST4 (1), ST15 (1), ST17 (4), ST25 (1), ST29 (13), ST48 (2), ST111 (1), ST186 (1), ST277 
(1), ST298 (1), ST307 (1), ST348 (1), and ST485 (2). Additionally, two potentially new allele 
combinations were found. Detailed results are listed in table 4.2. 
Table 4.2: MLST results. Isolate ID, allele combinations and sequence type is given for each isolate. All allele combinations 
were found at the Pasteur database, with the exception of the two possibly new combinations (ID 32 and 48). 
Group ID rpoB gapA mdh pgi phoE infB tonB ST 
C
T
X
-M
-1
5
 g
ro
u
p
 
10 4 2 2 2 6 3 4 29 
13 1 2 1 1 7 1 12 485 
14 3 3 1 1 3 1 1 4 
16 4 2 1 37 45 1 9 186 
17 4 2 1 1 4 1 4 17 
18 4 2 1 1 4 1 4 17 
19 1 2 1 1 7 1 12 485 
20a 4 2 1 1 4 1 4 17 
20b 4 2 1 1 4 1 4 17 
22 4 2 1 1 10 1 13 25 
25 1 3 1 1 1 1 43 277 
29 4 2 5 1 17 1 42 111 
32 4 4 2 1 9 1 12 New 
35 15 2 20 1 12 1 16 348 
37 1 1 1 1 1 1 1 15 
40 1 4 2 52 1 1 7 307 
45 1 2 2 1 1 1 7 298 
47 1 2 2 2 7 5 10 48 
48 4 2 17 1 20 6 25 New 
55 1 2 2 2 7 5 10 48 
S
H
V
-5
 g
ro
u
p
 
1a 4 2 2 2 6 3 4 29 
1b 4 2 2 2 6 3 4 29 
4 4 2 2 2 6 3 4 29 
6 4 2 2 2 6 3 4 29 
7 4 2 2 2 6 3 4 29 
11 4 2 2 2 6 3 4 29 
12 4 2 2 2 6 3 4 29 
15 4 2 2 2 6 3 4 29 
36 4 2 2 2 6 3 4 29 
42 4 2 2 2 6 3 4 29 
46 4 2 2 2 6 3 4 29 
54 4 2 2 2 6 3 4 29 
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4.4 Detection of plasmid replicon types  
 
PBRT was performed on the CTX-M-15 group isolates to detect 27 different plasmid replicon types. 
Additionally, the M6 PCR (Inc U, X1, R, and FIIK) was performed on the SHV-5 group isolates to 
screen for the presence of IncFIIK plasmids. Replicon types detected are listed in table 4.3. In general, 
the most dominant replicon types were IncFIIK and IncFIB. The CTX-M-15 group isolates contained 
1-3 replicon types. All SHV-5 group isolates were positive for IncFIIK. 
Table 4.3: PCR-based replicon typing results. 
ESBL ID Replicon type ID Replicon type 
C
T
X
-M
-1
5
 g
ro
u
p
 
10 R, FII, FIIK 25 FIB, FIIK 
13 I1, FIIK 29 FIB, FIIK 
14 I1, FIIK 32 FIB, FIIK 
16 FIB, R 35 FIB, FIIK 
17 R, FIIK 37 FIIK 
18 R, FIIK 40 FIB 
19 I1, FIB, FIIK 45 FIB, FIIK 
20a R, FIIK 47 FIIK 
20b R, FIIK 48 FIB, FIIK 
22 FIB, FIIK 55 R, FIIK 
S
H
V
-5
 
g
ro
u
p
 
1a FIIK 12 FIIK 
1b FIIK 15 FIIK 
4 FIIK 36 FIIK 
6 FIIK 42 FIIK 
7 FIIK 46 FIIK 
11 FIIK 54 FIIK 
 
4.5 Detection of plasmid number and sizes 
 
The CTX-M-15 group and SHV-5 group isolates were subjected to S1 – PFGE to detect any similar 
plasmids. A ~230 kbp plasmid was detected in all SHV-5 group isolates. Several plasmids of different 
sizes were detected among the CTX-M-15 group isolates (figure 4.1). 
 
Figure 4.1: S1-PFGE of the CTX-M-15 group isolates (A and B) and the SHV-5 group isolates (C). First and last lanes in 
each picture are the low-range ladders (New England Biolabs). Each band of the low-range ladder is sized to the far left 
(kbp).In the sample lanes one band represents one plasmid. Similarly sized plasmids are visible on image C (~ 230 kbp), see 
arrow. Plasmids across five isolates in the first image are of the same approximate size (~ 170 kbp and 70 kbp), as indicated 
by the arrows. 
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4.6 Location of ESBLA – encoding genes on specific plasmids 
 
Southern blot was used to link the ESBLA – encoding gene in the CTX-M-15 and SHV-5 group 
isolates to a specific plasmid, and furthermore to determine the size and replicon type of the plasmid 
carrying the ESBLA – encoding gene. Southern blot hybridization was successful on two of six 
membranes, one membrane applying the blaCTX-M probe and one membrane applying the blaSHV probe. 
Hybridization with IncFIIK probe on three membranes and one membrane with blaCTX-M probe gave no 
colorimetric signals. In the SHV-5 group isolates the ESBLA – encoding gene was carried by a ~230 
kbp plasmid (figure 4.2). Plasmids bearing the blaCTX-M-15 gene were found to be of diverse sizes. 
 
Figure 4.2: S1-PFGE of SHV-5 (A) and CTX-M-15 (C) group isolates and Southern blot hybridization with blaSHV probe (B) 
and blaCTX-M probe (D). Low range PFG marker (New England Biolabs) band sizes are listed on the left (kbp). The blaSHV-
hybridized bands were approximately 230 kbp, indicated by the arrow in A and B. The blaCTX-M hybridized bands ranged 
from 80 to 170 (arrow in C and D) kbp. 
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4.7 Capsular typing and virulence gene screening 
 
The SHV-5 group isolates were screened for capsular types and virulence genes commonly present in 
hypervirulent K. pneumoniae strains by PCR and gel electrophoresis (figure 4.3). None of the capsular 
types or virulence genes screened for was detected. 
 
Figure 4.3: Results for capsule typing and virulence gene detection of the SHV-5 group isolates. L1 and L2 are 50 bp and 
100 bp plus ladders (Qiagen), respectively. NC1 = negative control 1, a K. pneumoniae isolate negative for all targeted genes 
except Kpn 16S rRNA. NC2 is a contamination control with water. All isolates were positive for the Kpn 16S rRNA, but no 
capsule type or virulence genes were detected. Genes with positive controls are marked with arrows. Ghost bands are present 
on almost all isolates, approximately 280 bp. 
 
4.8 Summary of results 
 
The most relevant results are summarized in figure 4.4, a phylogenetic tree devised from the band 
relations detected by XbaI – PFGE.  
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Figure 4.4: An overview of PFGE patterns, STs, ESBLA – encoding genes, ESBLA – bearing plasmids and co-resistance to 
relevant antibiotics. PFGE band patterns are compared by the Dice coefficient and 1.5 % positional tolerance. Clustering 
analysis was performed by UPGMA. Percentage similarity reference is placed at the upper left. N = nitrofurantoin, ST = 
trimethoprim/sulfamethoxazole, C = ciprofloxacin, G = gentamicin, T = tobramycin.*ESBL-bearing plasmid not identified. 
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5. Discussion 
 
In this study, all clinical ESBLA-producing K. pneumoniae isolates isolated at the Department of 
Medical Microbiology at Stavanger University Hospital between 2003 and 2012 were characterized to 
get an overview of the most common ESBLA – encoding genes in this collection, and also to identify 
possible clones and/or plasmids which may have contributed to the dissemination of ESBLA among K. 
pneumoniae in the Stavanger region and -hospital. 
5.1 Methodical discussion 
 
The CTX-M-15 enzymes are the most widespread of the ESBLA-enzymes. Thus, in this study, we 
intended to select all blaCTX-M-15 positive isolates for more detailed molecular characterization, i.e. 
MLST and plasmid analysis. As we disclosed clonal relatedness between several blaSHV-5 positive 
isolates, it was decided to also include these isolates for more detailed analysis. 
Three of the isolates included in this study (ID 17, 18 and 19) had been isolated during an outbreak in 
Stavanger University Hospital in 2008 – 2009. These isolates were included to investigate if other 
isolates in this collection were related to the outbreak strains. 
5.1.1  PCR  
ESBLA gene PCR 
The following ESBLA genes were identified: blaCTX-M-15, blaCTX-M-3, blaSHV-2, blaSHV-2A, blaSHV-5, and 
blaSHV-12. The CTX-M group of two isolates could not be defined because no amplification was 
detected in the RT-PCR. There are many groups of blaCTX-M genes. It is possible that the untypeable 
blaCTX-M genes were from another group, and was not detected by the blaCTX-M-1 and blaCTX-M-9 group 
specific RT-PCRs. Three isolates, which had their CTX-M group defined, could not be identified 
through sequencing. Two of the three isolates were of the CTX-M-9 group. These were not sequenced 
because of the main interest in the CTX-M-1 group. The last of the three was a group 1 CTX-M, but 
was not amplified in the blaCTX-M group 1 specific PCR and was therefore not sequenced. The reason for 
this might be that the gene in this isolate is a variant that is not detected by the primers, or the genetic 
environment around the gene itself might be different, which means the primers might not anneal to 
the target. 
The blaSHV gene was not detected in all isolates. This may be due to isolates simply being blaSHV 
negative. Similar results were presented by Alibi et al. in 2015, where blaSHV genes were detected in 
89 % of the isolates analysed [3]. Only 14.28 % of ESBL-positive K. pneumoniae were found to be 
blaSHV positive by Gholipour et al. in 2014 [38], suggesting that the results found in this study are as 
expected. 
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Some PCR programs had to be adjusted to fit the chemistry of the HotStarTaq master mix kit 
polymerase (Qiagen), specifically MLST and IncFIIK PCRs. The HotStarTaq polymerase needs a 15 
minute initiation phase at 95 °C to activate, and the PCR programs were adjusted accordingly. 
MLST 
The MLST PCR running conditions were described at the Pasteur website, along with the primers. The 
website states the tonB gene PCR needs a 50 mM MgCl2 concentration, while all the other genes need 
25 mM MgCl2 for primers to work. However, in this study PCR products were amplified on all genes 
with the use of HotStarTaq master mix kit, which contains 3 mM MgCl2. 
5.1.2  Sanger sequencing 
Two different ESBL variants of blaCTX-M group 1 genes were identified through sequencing. Additionally, 
six different ESBL variants of blaSHV genes were identified. No ESBL variants of blaTEM were 
identified. 
Sequencing blaSHV genes was not as simple as sequencing the blaCTX-M, because of the chromosomal 
non-ESBL blaSHV gene present in almost all K. pneumoniae isolates, which leads to a mixed signal, or 
double peaks, when sequencing. Chromosomal genes are present in only one copy, while a plasmid-
borne blaSHV would have a higher copy number (depending on the plasmid being a low-copy or high-
copy number plasmid). Thus, the plasmid-borne blaSHV genes produce a higher signal than 
chromosomal blaSHV, and the sequences could be differentiated. In this study, double peaks were 
present in almost all isolates carrying an ESBL type blaSHV, suggesting the presence of chromosomal 
blaSHV genes. To completely resolve this problem, one could isolate the plasmid DNA and run a PCR 
targeting the blaSHV gene. With no part of the chromosome present, no double peaks should be seen.  
Haanperä et al. has previously described another solution to this problem [41]. The article describes 
the use of pyrosequencing at positions 238 and 240, which are the known amino acid positions for 
substitutions that lead to an ESBL phenotype (Ambler numbering scheme, [5]). This area is also the 
area where double peaks were observed in this study. Pyrosequencing is therefore a technique that 
might be useful to define SHV type ESBL genes in K. pneumoniae.  
Additional sequencing primers were used to cover the whole gene sequence of the blaTEM and blaSHV 
genes, as the initial PCR primers were insufficient. The blaCTX-M-1 gene was sequenced using three 
primers.  One blaCTX-M positive isolate was not amplified by the blaCTX-M group 1 specific PCR without 
changing the forward primer to ISEcp-tnpA3-F, due to the different genetic environment of that isolate. 
5.1.3  PFGE – XbaI and S1-nuclease 
PFGE was performed on all isolates, and two clones were detected. A phylogenetic tree was devised 
from the PFGE results. Band relations were calculated by the Dice coefficient with 1.5 % positional 
tolerance, and cluster analysis was done by UPGMA. These are the most commonly used criteria used 
for Klebsiella PFGE. Bands were marked manually in Bionumerics on the PFGE gels, which might 
affect the final phylogenetic tree. Care was therefore taken to place bands correctly, with a slightly 
lenient positional tolerance (1.5 %). 
Twelve isolates had to be run with thiourea in the running buffer for bands to appear, both on PFGE 
and S1-PFGE. This has been previously described as an effective solution for some bacterial species 
[87]. Reactive tris radicals from the running- and gel buffer seemingly have a degrading effect on 
DNA molecules over time, which may have been the cause for the smears appearing on the gel. The 
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addition of thiourea, either in the running buffer or the gel buffer, will increase the stability of the 
DNA molecules because thiourea scavenges the excess reactive tris radicals [78]. 
Originally, the S1-PFGE procedure describes the use of plugs made of low melting point agarose. 
However, plugs for PFGE had previously been made with SeaKem gold agarose. Therefore, the S1-
PFGE protocol was tested on the PFGE plugs, with success. The 12 isolates that produced smears on 
PFGE also did in the S1-PFGE. This was resolved by using new plugs with a higher bacterial 
concentration (~5 McFarland). New plugs with higher bacterial concentration were made for all S1-
gels used in Southern blot, which had a positive effect on the signal strength after detection. 
5.1.4  Southern blot hybridization 
Southern blot hybridization was successful on two of six membranes, one membrane applying the 
blaCTX-M probe and one membrane applying the blaSHV probe. Hybridization with IncFIIK probe on 
three membranes and one membrane with blaCTX-M probe gave no colorimetric signals. 
Labelling 
Three probes were made using the DIG-high prime DNA labelling and detection starter kit I. The 
labelled probes were fixed to a membrane for determination of sensitivity. If the 0.1 pg/µl dilution was 
visible, then the probe had the desired sensitivity for southern blot hybridization. The blaSHV probe 
was calculated to be very low in concentration (7.6 ng/ml). In spite of this, the blaSHV probe produced 
the clearest bands with just 30 minutes exposure to the colour substrate solution. Since the calculation 
of labelled probe concentration was partially based on visual input (colour forming on membrane), it is 
possible that calculations were slightly incorrect. 
Detection 
The blaCTX-M probe was not as sensitive as the blaSHV probe, as it seemed to need longer time for 
visible bands to appear. A lot more background was seen on the membrane hybridized with blaCTX-M 
probe. This is probably because the membrane had to be exposed to the colour substrate solution for a 
longer period of time, which might have visualized unspecific binding of antibodies. The addition of 
more probe mix to the hybridization solution for a higher concentration might have made bands appear 
faster, with less background. 
The IncFIIK probe did not give any colorimetric signal after hybridization and detection. The general 
temperature of 40 °C was used for all probes when hybridizing overnight. However, this may not be 
the optimal temperature for the IncFIIK probe, and may be one of many reasons why no bands 
appeared on the hybridized membrane. According to the manufacturer instructions for the DIG-high 
prime DNA labelling and detection starter kit I, the optimal hybridization temperature is calculated 
from GC content and percent homology of probe to target sequence, which is described by the 
following equations: 
TM = 49.82 + 0.41 (% G + C) – (600 / I), where I = length of hybrid in base pairs 
TOpt = TM – 20 to 25 °C 
The IncFIIK probe hybridization temperature was calculated to be 38.80 – 43.80 °C. A slightly 
increased hybridization temperature than 40 °C would have led to more specific bonding which may 
have led to hybridization of the probe. Probe sequence differences may result in a different optimal 
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hybridization temperature, which may be the reason for no bands appearing. In general, a lower 
temperature may lead to less specific bonding, and may also have been a solution for the problem. 
Transfer 
The vacuum transfer protocol had to be adjusted for complete transfer. The original protocol stated 
that 5 in Hg for 90 minutes was sufficient for complete transfer for generally all gels, but gel thickness, 
percentage, agarose type, and also template DNA size are factors that can affect the transfer. In this 
study, it was found that 5 in Hg was not enough pressure to successfully transfer plasmid DNA to the 
nylon membrane. The gel was dyed with ethidium bromide before and after transfer to see if the 
transfer was successful. By increasing the pressure to 10 in Hg, transfer of plasmid DNA was 
successful.  
5.2 Results discussion 
 
Several distinct ESBLA genes were identified by sequencing. Of the most abundant were the blaCTX-M-
15 and blaSHV-5 genes. Additionally, SHV-11 was identified in 11 isolates and SHV-1 in five. Since 
double peaks were found in many isolates, it is highly probable that SHV-1 or SHV-11 is present in 
these isolates as well. K. pneumoniae normally carry a chromosomal SHV-1 or SHV-11 encoding 
gene [6, 41]. Haanperä et al. detected two blaSHV genes in 95.3 % of the isolates analysed, where the 
SHV-1 and SHV-11 encoding genes were regarded as chromosomal [41]. Similar results were found 
in this study, as most isolates positive for an SHV-type ESBLA encoding gene had double peaks. 
However, the ESBLA-encoding genes were of main interest in this study.  
Two ESBLA-encoding genes were identified in two isolates (ID 25 and 35), namely blaCTX-M-15 and 
blaSHV-27 and blaSHV-2A, respectively. No ESBLA encoding gene was detected in two isolates (ID 9 and 
43). However, both isolates were given an ESBL phenotype from the Vitek 2 instrument. Isolate 9 had 
the non-ESBL blaSHV-11 gene, with resistance towards ceftazidime, but not cefotaxime. Isolate 43 was 
positive for the non-ESBL genes blaSHV-33 and blaTEM-57, and was resistant to both cefotaxime and 
ceftazidime. Since no ESBLA – encoding gene was identified, it is possible that these two isolates 
harbour the rare VEB or PER variants of ESBLA, which have not been tested for.  
Most CTX-M-15 group isolates were resistant to cefotaxime whereas most of the SHV-5 group 
isolates were resistant to ceftazidime. This is expected, as CTX-M- and SHV – enzymes are known to 
have the highest substrate affinity for cefotaxime and ceftazidime, respectively. A Gram-negative 
strain is regarded as multidrug resistant when it is resistant to three or more different groups of 
antibiotics [53]. The ST17 clone had identical co-resistance profiles (resistant to 
trimethoprim/sulfamethoxazole, nitrofurantoin, gentamicin and tobramycin). These four isolates were 
therefore regarded as multidrug resistant. This is probably attributed to the same ESBL-bearing 
plasmid in all four isolates. However, only six of the SHV – group isolates were multidrug resistant. 
This may be due to the presence of many different plasmids in these isolates, as seen on the S1-PFGE. 
The SHV-5 group isolates were isolated over a time period of nine years, during which the clone may 
have lost or gained new plasmids, depending on the environment of the clone. Different resistance 
genes may be present on the varying plasmids, thus giving different co-resistance profiles. 
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5.2.1 SHV-5 – group isolates 
The SHV – group isolates, collected between 2003 and 2012, were all found to be closely related by 
XbaI – PFGE. The nine fragments, ranging from ~480 – 730 kbp were identical in all 12 isolates, 
whereas the smaller fragments were of varying numbers and sizes. Depending on the mutational rate 
of a bacterial strain, the DNA sequence and also the PFGE-pattern of a clone is expected to change 
over the years. The SHV – group isolates were also of the same sequence type (ST29), which also 
suggests that these isolates may represent a SHV-5 producing K. pneumoniae clone, which has been 
present in the region and in the hospital environment for a long time, sporadically causing clinical 
infections.  
Hypermucoviscous K. pneumoniae ST29, of capsule type K54, has previously been described to cause 
mycotic aneurysm. This strain seemed to be highly virulent, but not particularly resistant to antibiotics 
[26]. As the SHV-5 producing strain detected in this study was highly mucoid and of ST29, screening 
of these isolates for the presence of virulence genes and K-types (including K54) known to be 
associated with hypermucoviscosity and/or hypervirulence was performed. None of the virulence 
genes or K-types screened for were detected. However, more than 70 capsule types are defined for K. 
pneumoniae, but only six were screened for. To determine the capsule type of this clone, one could 
perform a PCR targeting the capsule encoding operon and sequence the product [14]. None of the 
SHV-5 group isolates were positive for the virulence gene rmpA, which has been linked to a 
hypermucoviscous phenotype. The rmpA gene can be located either in the chromosome (c-rmpA) or 
on a plasmid (p-rmpA). A plasmid – borne variant of the rmpA gene, rmpA2, has also been described. 
It is possible that the SHV-5 group isolates carry rmpA2. However, the rmpA gene is usually related 
to the serotypes K1, K2, K5, K16, K20, K54, K57 and KN1, and is rarely associated with other 
serotypes [44]. 
SHV-5 producing K. pneumoniae has been found to cause outbreaks and sporadic infections in earlier 
studies [30, 54, 84]. Prodinger et al. detected an 80 kbp, blaSHV-5 bearing plasmid in outbreak isolates 
of K. pneumoniae in 1996 [71]. Plasmid transfer was associated with the dissemination of the blaSHV-5 
gene, as it had also spread to other bacteria (E. coli and K. oxytoca). However, in another study, clonal 
spread of a blaSHV-5 bearing plasmid was described, causing sporadic infections in different hospital 
wards [9]. The plasmid was found to be stable over time, and also harboured resistance genes that 
conferred resistance towards gentamicin and trimethoprim/sulfamethoxazole. Additionally, all isolates 
analysed had the capsule type K1. Since the strain was detected in a stool sample, it was suggested that 
the mode of transmission was from faecal contamination. An SHV-5 producing K. pneumoniae strain 
with ST20 has previously been described as the causative agent of a neonatal intensive care unit 
outbreak in Greece [57]. 
The blaSHV-5 positive ST29 clone (SHV-5 group) seems to be a stable clone, and might be considered 
endemic in the Stavanger region and in the hospital environment in the period 2003 – 2012. 
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5.2.2 CTX-M-15 – group isolates 
The phylogenetic tree devised from PFGE data suggests a high degree of diversity among the CTX-M-
15 group isolates as only a few isolates had similar or closely related PFGE patterns (≥80 % similarity). 
As expected, the two isolates (ID number 17 and 18 and ST17) from the outbreak in the neonatal 
intensive care unit in 2008 – 2009 were indistinguishable by PFGE, with 100 % similarity. 
Additionally, isolate 20a and b (also ST17) had related PFGE patterns, but with lower similarity to one 
another and the outbreak isolates. Isolate 20a and b were also recovered in 2009, but from a patient 
admitted to another ward. It is unknown if there was any link between the two wards, or between the 
patient from whom isolate 20a and b were recovered and any neonatal intensive care unit patient. 
The blaCTX-M-15 gene was identified on plasmids ranging from 80 to 180 kbp. Various sizes and 
replicon types of blaCTX-M-15 bearing plasmids have previously been described [27, 33, 75, 90]. In this 
study, the replicon type of the blaCTX-M-15 bearing plasmids could not be determined. The blaCTX-M-15 
gene is mainly associated with IncFII plasmids in K. pneumoniae [47]. However, since isolate 17, 18, 
20a and 20b (170 kbp plasmid bearing blaCTX-M-15, ST17) was from the outbreak in 2008 – 2009, the 
ESBLA gene was located on an IncFIIK plasmid, as previously described [49].  
Most of the CTX-M-15 group isolates were not clonally related, and carried blaCTX-M-15 encoding 
plasmids of different sizes (~70 – 230 kbp). This seems to be in accordance with the global picture of 
the dissemination of blaCTX-M-15 genes, as it has been found to be connected to various clones [66] and 
plasmids of different sizes and replicon types. 
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6. Conclusions 
 
- The most prevalent ESBLA-encoding genes among clinical K. pneumoniae isolates from 
patients in the Stavanger region were blaCTX-M-15 and blaSHV-5. 
 
- The ST29, blaSHV-5 positive clone seemed to have persisted in the Stavanger region and 
hospital environment in the period 2003 – 2012 
o This may represent an endemic clone in the region 
o The clone has caused sporadic infections, especially in the hospital setting 
 
- The ST17, blaCTX-M-15 positive clone, which caused an outbreak in the hospital in 2008 – 2009, 
was only identified in one patient not associated with the outbreak. Thus, this clone does not 
seem to have become endemic, at least not among clinical isolates, in the Stavanger region 
 
- The blaCTX-M-15 gene was associated with diverse clones and plasmids in clinical isolates in the 
Stavanger region  
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7. Future prospective 
 
The results from this study may have a diagnostic consequence. Knowledge of dominating ESBLA 
genes (blaCTX-M-15 and blaSHV-5) is needed if new molecular (PCR) methods are to be developed, for 
quick detection of common ESBLA genes in clinical samples. The development of such methods may 
have a therapeutic consequence, and thus of great importance for the patient.  
In this study, K. pneumoniae clones which have caused infections were identified (for example ST29). 
Whether or not the clone has caused an outbreak is unknown, but it seems to have persisted in the 
hospital environment and caused sporadic infections. This may be useful information for future 
infection control measures. 
For future studies, all methods may be applied to this collection of isolates for full identification of 
potential clones, similar plasmids and full ESBLA gene profile. Also, the inclusion of newer isolates 
from 2013 – 2015 may be of interest, to ascertain whether the ST29 clone is still persistent in the 
hospital environment.  
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Appendix A – Primers, PCR-
controls and recipes 
 
  
 
 
Table A.1: List of all primers used in this study.  
 Use Gene Primer name Sequence Size (bp) Ref. 
Bacterial 
detection 
 
16S 
16S F AGA GTT TGA TCC TGG CTC AG 
 512 [55] 16S R GTA TTA CCG CGG CTG CTG 
 
 
P
C
R
 &
 
E
S
B
L
A
 -
 g
en
e 
se
q
u
en
ci
n
g
 
 
blaCTX-M 
blaCTX-M F SCS ATG TGC AGY ACC AGT AA 
 585 [81] blaCTX-M R ACC AGA AYV AGC GGB GC 
 
 
 
 
blaCTX-M 
group 1 
CTX-M-1 F GGT TAA AAA ATC ACT GCG TC 
 
800 - 
1700 
[34] 
CTX-M-1 R TTG GTG ACG ATT TTA GCC GC 
 
ISEcp1-tnpA1 F AAT ACT ACC TTG CTT TCT GA 
 
ISEcp1-tnpA2 F TCA TTT TTG GGC GAA TGA AGC 
 
ISEcp1-tnpA3 F CAG CAA ATA AAG ACC TTT CGT 
 
Orf477 R GGT GGC ATA ATT TTT GAA GT 
 
 
 
blaSHV 
blaSHV F ATG CGT TAT ATT CGC CTG TG 
 862 [81] blaSHV R AGC GTT GCC AGT GCT CGA TC 
 
Core SHV F GGC CGC GTA GGC ATG ATA GA 
 714 [64] 
Core SHV R CCC GGC GAT TTG CTG ATT TC 
 
 
 
blaTEM 
blaTEM F ATG AGT ATT CAA CAT TTC CG 
 858 [81] blaTEM R CCA ATG CTT AAT CAG TGA GG 
 
TEM F extra TCA TGT AAC TCG CCT TGA TCG T 
 
 This 
study TEM R extra ACG CTC GTC GTT TGG TAT GG 
 
 
 
M
u
lt
il
o
cu
s 
se
q
u
en
ce
 t
yp
in
g
 
 
rpoB 
VIC3 GGC GAA ATG GCW GAG AAC CA 
 501 
 
 
 
 
 
 
 
[32] 
VIC2 GAG TCT TCG AAG TTG TAA CC 
 
 
gapA 
gapA173 TGA AAT ATG ACT CCA CTC ACG G 
 450 
gapA181 CTT CAG AAG CGG CTT TGA TGG CTT 
 
mdh 
mdh130 CCC AAC TCG CTT CAG GTT CAG 
 477 
mdh867 CCG TTT TTC CCC AGC AGC AG 
 
 
 
pgi 
pgi1F GAG AAA AAC CTG CCT GTA CTG CTG GC 
 
432 
pgi1R CGC GCC ACG CTT TAT AGC GGT TAA T 
 
pgi2F (Seq) CTG CTG GCG CTG ATC GGC AT 
 
pgi2R (Seq) TTA TAG CGG TTA ATC AGG CCG T 
 
 
phoE 
phoE604.1 ACC TAC CGC AAC ACC GAC TTC TTC GG 
 420 
phoE604.2 TGA TCA GAA CTG GTA GGT GAT 
 
 
 
infB 
infB1F CTC GCT GCT GGA CTA TAT TCG 
 
318 infB1R CGC TTT CAG CTC AAG AAC TTC 
 
infB2F (Seq) ACT AAG GTT GCC TCC GGC GAA GC 
 
 
tonB 
tonB1F CTT TAT ACC TCG GTA CAT CAG GTT 
 414 
tonB2R ATT CGC CGG CTG RGC RGA GAG 
 
Probe* 
 
FIIK 
FIIK FW TCT TCT TCA ATC TTG GCG GA 
 142-148 [86] 
FIIK RV GCT TAT GTT GCA CRG AAG GA 
 
C
a
p
su
la
r 
ty
p
in
g
 
 
K1 
MagAF1 GGTGCTCTTTACATCATTGC 
 1283 [35] 
MagAR1 GCAATGGCCATTTGCGTTAG 
 
 
K2 
K2wzy-F1 GACCCGATATTCATACTTGACAGAG 
 641 
[82] 
K2wzy-R1 CCTGAAGTAAAATCGTAAATAGATGGC 
 
 
K5 
K5wzxF360 TGGTAGTGATGCTCGCGA 
 280 
K5wzxR639 CCTGAACCCACCCCAATC 
 
 
K54 
wzxK54F CATTAGCTCAGTGGTTGGCT 
 881 
 
 
[36] 
wzxK54R GCTTGACAAACACCATAGCAG 
 
 
K57 
wzyK57F CTCAGGGCTAGAAGTGTCAT 
 1037 
wzyK57R CACTAACCCAGAAAGTCGAG 
 
 
K20 
wzyK20F CGGTGCTACAGTGCATCATT 
 741 
wzyK20R GTTATACGATGCTCAGTCGC 
 
 
rmpA 
rmpAF ACTGGGCTACCTCTGCTTCA 
 516 [61] 
rmpAR CTTGCATGAGCCATCTTTCA 
 
 
wcaG 
wcaGF GGTTGGKTCAGCAATCGTA 
 169 [83] 
wcaGR ACTATTCCGCCAACTTTTGC 
 
 
K. pn 16S 
K. pn Pf ATTTGAAGAGGTTGCAAACGAT 
 130 [48] K. pn Pr1 TTCACTCTGAAGTTTTCTTGTGTTC 
 
*Probe for southern blot 
 
 
Table A.2: PCR controls used in this study. 
Target PCR Content Origin 
 
16S rRNA 
 
K. pneumoniae bacterial DNA In-house 
 
blaCTX-M, blaSHV, blaTEM 
 
K. pneumoniae strain positive for 
blaCTX-M, blaTEM and blaSHV 
In-house 
 
CTX-M-1 RT-PCR 
 
K. pneumoniae strain positive for 
blaCTX-M group 1 
In-house 
 
CTX-M-9 RT-PCR 
 
K. pneumoniae strain positive for 
blaCTX-M group 9 
In-house 
 
Capsular typing 
 
K. pneumoniae positive for K1, 
rmpA and wcaG 
In-house 
 
 
Table A.3: In-house recipes for media used in this study. 
Agar Ingredients Per litre 
B
lo
o
d
 
 
Blood agar base no. 2 (Oxoid) 
 
40.0 g 
Distilled water 1000 ml 
Human blood 62.5 ml (5.9 %) 
 
M
o
d
if
ie
d
 M
ac
C
o
n
k
ey
 
 
Bact Agar (Oxoid) 
 
18.75 g 
Peptone Gelatine (Merck) 6.25 g 
Peptone Casein (Merck) 3.75 g 
Beef Extract (Lab Lemco) 6.5 g 
Sodium Chloride (VWR) 5.0 g 
5.0 M Sodium Hydroxide 2.25 ml 
Distilled water 1000 ml 
Crystal Violet solution (1.0 %) 5.0 ml 
Lactic acid concentrate (VWR) 0.75 ml 
Lactose (Merck) 10.0 g 
Sodium Thiosulfate 1.0 g 
Bromothymol Blue solution (2.5 %) 40.0 ml 
 
M
u
el
le
r 
H
in
to
n
  
Mueller Hinton II Agar (BBL) 
 
38.0 g 
Distilled water 1000 ml 
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Table A.4: MALDI-TOF identification results.  
ID Species Score ID Species Score 
1a K. pneumoniae 2.479 28 K. pneumoniae 2.451 
1b K. pneumoniae 2.450 29 K. pneumoniae 2.200 
2 K. pneumoniae 2.321 32 K. pneumoniae 2.237 
3 K. pneumoniae 2.431 33 K. pneumoniae 2.364 
4 K. pneumoniae 2.512 34 K. pneumoniae 2.094 
5 K. pneumoniae 2.226 35 K. pneumoniae 2.242 
6 K. pneumoniae 2.451 36 K. pneumoniae 2.263 
7 K. pneumoniae 2.526 37 K. pneumoniae 2.326 
8 K. pneumoniae 2.367 38 K. pneumoniae 2.294 
9 K. pneumoniae 2.479 39 K. pneumoniae 2.325 
10 K. pneumoniae 2.395 40 K. pneumoniae 2.249 
11 K. pneumoniae 2.365 42 K. pneumoniae 2.300 
12 K. pneumoniae 2.273 43 K. pneumoniae 2.151 
13 K. pneumoniae 2.293 44 K. pneumoniae 2.421 
14 K. pneumoniae 2.265 45 K. pneumoniae 2.373 
15 K. pneumoniae 2.357 46 K. pneumoniae 2.357 
16 K. pneumoniae 2.360 47 K. pneumoniae 2.094 
17 K. pneumoniae 2.257 48 K. pneumoniae 2.300 
18 K. pneumoniae 2.337 51 K. pneumoniae 2.151 
19 K. pneumoniae 2.389 53 K. pneumoniae 2.344 
20a K. pneumoniae 2.299 54 K. pneumoniae 2.255 
20b K. pneumoniae 2.333 55 K. pneumoniae 2.328 
22 K. pneumoniae 2.166 56 K. pneumoniae 2.014 
23 K. pneumoniae 2.251 57 K. pneumoniae 2.299 
25 K. pneumoniae 2.346    
 
  
 
 
Table A.5: VITEK 2 antimicrobial susceptibility testing results.  
ID Phenotype AMP TMP NIT SXT CIP CXM CTX CAZ GEN TZP FOX AMC CXA AZT NAL TOB 
1a ESBL R S S S I R R R R R R R R R R R 
1b ESBL R R R S R R R R R I R S R R R R 
2 ESBL R S S S S R R S S S S S R I S S 
3 ESBL R I S S S R R R S R R R R R R S 
4 ESBL R S S S I R I R R R S S R R R R 
5 ESBL R S S S S R R I I S S S R R S R 
6 ESBL R S S S I R I R I I R S R R R R 
7 ESBL R S S S I R I R I I R S R R R R 
8 ESBL R R S R S R R I R I S R R R S R 
9 ESBL R R S S R S S R R R S R S S R R 
10 ESBL R R S R R R R R R R R R R R R R 
11 ESBL R S R S I R R R R R S S R R R R 
12 ESBL R S S S I R R R R I R S R R R R 
13 ESBL R R R R S R R R S S S R R R S S 
14 ESBL R R S R S R R R R R S R R R S R 
15 ESBL R S R S I R R R R R S S R R R R 
16 ESBL R R S R I R R I R S S S R R S R 
17 ESBL R R R R S R R R R R S R R R S R 
18 ESBL R R R R S R R R R R S R R R S R 
19 ESBL R R S R S R R R S S S R R R S S 
20a ESBL R R R R S R R R R R S R R R S R 
20b ESBL R R R R S R R R R R S R R R S R 
22 ESBL R R S R S R R R S S S S R R S S 
23 ? R R S R S S S S S S S S S S S S 
25 ESBL R R S R I R R R R I S R R R S R 
28 ESBL R R S S S R R I S S S R R R S S 
29 ESBL R R R R R R R R S R S R R R R R 
32 ESBL R R R R R R R R R I S R R R R R 
33 ESBL R S S S S R R S S S S S R S S S 
34 ESBL R R S R S R R R R S S R R R S R 
35 ESBL R R R R S R R R R R S R R R S R 
36 ESBL R S R S R R I R R R R R R R R R 
37 ESBL R R S R R R R I S I S R R R R R 
38 ESBL R R R R R R R R S I R S R R R S 
39 ? R R R R S S S S R S S S S S R R 
40 ESBL R R R R R R R R R I S R R R R R 
42 ESBL R S S S I R S R R I S S R R R R 
43 ESBL R S R S I R R R S S S R R R S S 
44 ESBL R S S S S R R R S S S S R R S S 
45 ESBL R R S R S R R R R S S S R R S R 
46 ESBL R S S S I R S R R I S S R R R R 
47 ESBL R R S R S R R R R R S R R R S R 
48 ESBL R R S R R R R I R I S R R R R R 
51 ESBL R R R R R R R R S S S S R R R S 
53 ESBL R S S S S R R R R S S S R R S R 
54 ESBL R S R S I R S R R I R S R R R R 
55 ESBL R R S R S R R R S S S S R R S S 
56 ESBL R S R S S R R I S I S R R R R S 
57 ESBL R R R R R R R R S R S R R I R S 
 
AMP = ampicillin, TMP = trimethoprim, NIT = nitrofurantoin, SXT = trimethoprim/sulfamethoxazole, CIP = ciprofloxacin, 
CXM = cefuroxime, CTX = cefotaxime, CAZ = ceftazidime, GEN = gentamicin, TZP = piperacillin/tazobactam, Fox = 
cefoxitin, AMC = amoxicillin/clavulanic acid, CXA = cefuroxime axetil, AZT = aztreonam, NAL = naldixic acid, Tob = 
tobramycin. R = resistant, I = intermediate, S = sensitive. 
 
 
 
 
Table A.6: Manual antibiotic susceptibility testing by disk diffusion. 
Panel Antimicrobial compound 23 39 
C 
AMP R R 
SXT R R 
CIP S S 
CTX R I 
CAZ I R 
D 
GEN S R 
CEF R R 
TZP S S 
MER S S 
ESBL 
CAZ / Caz + Clav. 3 mm* 6 mm* 
CTX / CTX + Clav. 7 mm* 7 mm* 
FOX S S 
 
* Isolates were positive for the ESBL test (in the ESBL panel) if differential diameter were above 5 mm. 
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